β-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates

ABSTRACT

An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula: 
     
         G-D-R 
    
     wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product, usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a β-galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format.

CROSS-REFERENCE TO RELATED APPLICATION

This is a division of application Ser. No. 87,819, filed Oct. 23, 1978,now U.S. Pat. No. 4,279,992, which is a continuation-in-part ofapplication Ser. No. 886,094, filed Mar. 13, 1978, now U.S. Pat. No.4,226,978.

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

This invention relates to assay methods, and reagent means for usetherein, of the homogeneous and heterogeneous specific binding type fordetermining qualitatively or quantitatively a ligand in a liquid medium.In particular, the invention relates to an improved nonradioisotopicbinding assay employing a novel enzyme substrate label.

2. DESCRIPTION OF THE PRIOR ART

In German Offenlegungschriften Nos. 2,618,419 and 2,618,511,corresponding respectively to U.S. Patent Applications Ser. Nos. 667,982and 667,996, both filed Mar. 18, 1976, both now abandoned and assignedto the present assignee, there are described homogeneous andheterogeneous specific binding assays employing an enzyme-cleavablesubstrate label. In exemplified embodiments there are disclosed the useof fluorogenic-labeled conjugates comprising umbelliferone orfluorescein coupled via an ester group to a ligand under assay or to abinding partner therefor. The amount of labeled conjugate in thebound-species and/or free-species resulting from the binding reactionsystem employed is determined by addition of an esterase which cleavesthe ester group linking the umbelliferone or fluorescein residue to theligand or binding partner to release the free fluorescent products,umbelliferone and fluorescein, respectively. The rate of fluorescenceproduction, which follows the rate of release of the fluorescentproduct, is a function of the amount of ligand in the liquid mediumtested.

Performance of this assay depends upon the ability to determine theamount of labeled conjugate which results in either the bound-species orthe free-species relative to the amount initially introduced. Where themeasured character of the labeled conjugate in the bound-species isessentially indistinguishable from that in the free-species, the twospecies must be physically separated in order to complete the assay.This type of binding assay follows what is conventionally known as a"heterogeneous" format. On the other hand, where the measured characterof the labeled conjugate in the two species is distinguishable, a"homogeneous" format can be followed if desired and the separation stepavoided.

While the above described binding assays employing an enzyme-cleavablesubstrate label offer a generic, novel approach to the pertinent art,the application of the assays to the detection of ligands in certaintypes of liquid media using the ester linked labeled conjugate isrestricted. For example, the ester based assay has been found to beinconvenient for the detection of ligands appearing in the milligram perliter concentration range in physiological fluids such as serum andplasma. It has been found in this situation that the fluid under assaycan contain a high endogenous esterase activity and, independently, theester linked conjugate can exhibit a significant instability as theresult of background hydrolysis under the conditions of the assay, whichare usually alkaline.

SUMMARY OF THE INVENTION

It has now been found that the specific binding assay employing anenzyme-cleavable substrate label is greatly improved by the use of thenovel label component described herein in formation of the labeledconjugate. According to the previously described assay method, theliquid medium under assay for a particular ligand is combined withreagent means, including a conjugate having a label component and abinding component, to form a binding reaction system having a boundspecies and a free-species of such labeled conjugate, the labelcomponent of the conjugate comprising an enzyme-substrate active portionand an indicator portion, whereby the conjugate is cleavable by anenzyme to produce a detectable indicator product. The resultingbound-species and/or the free-species is contacted with the cleavingenzyme and the resulting indicator product measured as a function of thepresence or amount of the ligand to be determined in the liquid mediumassayed.

The present improvement comprises employing as the label component ofthe conjugate, a residue of the formula:

    G-D-R

wherein G is a glycone, D is a dye indicator moiety, and R is a linkinggroup through which the dye indicator moiety is covalently bound to thebinding component of the conjugate. The cleaving enzyme employed tomonitor the label in the bound-species or free-species accordingly isone capable of cleaving the glycosidic linkage between the glycone andthe dye indicator moiety. The most preferred glycone and dye indicatormoiety for the labeled conjugate are, respectively, a β-galactosyl groupand an umbelliferone residue. The assay is adaptable to the detection ofany specifically bindale ligand and is particularly useful in thedetection of haptens, such as drugs, and antigenic proteins andpolypeptides, including antibodies.

In a particularly preferred embodiment, the present invention provides ahomogeneous specific binding assay method for determining a ligand in aliquid medium, wherein the liquid medium is combined with (1) a labeledconjugate comprising the ligand or a binding analog thereof coupled to alabel component, which label component comprises an enzymesubstrate-active portion and an indicator portion whereby the labeledconjugate is cleavable by an enzyme to produce a detectable indicatorproduct, (2) a specific binding partner of the ligand, the labeledconjugate being inactive as a substrate for the enzyme when bound by thebinding partner of the ligand, and (3) the cleaving enzyme, and whereinthe resulting indicator product is measured as a function of the amountof the ligand in the liquid medium, the improvement comprising employingas the label component of the conjugate, a residue having the formula:

    G-D-R

wherein G is a β-galactosyl group, D is a dye indicator moiety, and R isa linking group through which the dye indicator moiety is covalentlybound to the ligand or analog thereof, and employing β-galactosidase asthe cleaving enzyme whereby the β-galactosyl group may be cleaved torelease a detectable dye product.

In an alternative preferred embodiment, the present invention provides ahomogeneous specific binding assay method for determining a ligand in aliquid medium, wherein the liquid medium is combined with (1) a labeledconjugate comprising a specific binding partner of the ligand coupled toa labeled component, which label component comprises an enzymesubstrate-active portion and an indicator portion whereby the labeledconjugate is cleavable by an enzyme to produce a detectable indicatorproduct, the labeled conjugate being inactive as a substrate for theenzyme when bound by the ligand, and (2) the cleaving enzyme, andwherein the resulting indicator product is measured as a function of theamount of the ligand in the liquid medium, the improvement comprisingemploying as the label component of the conjugate, a residue having theformula:

    G-D-R

wherein G is a β-galactosyl group, D is a dye indicator moiety, and R isa linking group through which the dye indicator moiety is covalentlybound to the binding partner, and employing β-galactosidase as thecleaving enzyme whereby the β-galactosyl group may be cleaved to releasea detectable dye product.

The present invention also provides reagent means and labeled conjugatesfor use in carrying out the improved assay method.

The presently improved assay method and means feature the advantages ofinvolving a cleaving enzyme for which negligible, if any, endogenousactivity is found in physiological fluids such as serum and plasma, andof employing a labeled conjugate wherein the cleavable linkage is verystable under assay conditions in the absence of enzyme. For thesereasons the present invention ioffers a significantly more accurate andreproducible assay than that previously known in the art. Further,antibody-induced hydrolysis of the cleavable linkage, which hydrolysisis sometimes found using the ester-linked labeled conjugates, is absentusing the present glycosidic-linked conjugates. Even further, thereagents necessary for performing the assay generally exhibit greaterstability, particularly the labeled conjugate, than prior reagents. Theglycosidase enzymes involved in the present invention generally arestable over long storage periods and in dilute solutions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the basic principles of aspecific binding assay employing an enzyme-cleavable substrate label asapplied to the immunoassay determination of a drug wherein the cleavedproduct is fluorescent.

FIG. 2 is a graphical representation of the effect of increasingantibody concentration on the rate of release of cleaved product from alabeled conjugate for use in an assay for gentamicin as described inExample 1.

FIG. 3 is a graphical representation of the relation between gentamicinconcentration and reaction rate as determined using standards asdescribed in Example 1 for use as a standard curve in a rate assay forgentamicin.

FIGS. 4-15 are graphical representations of the relations between theconcentration of the various ligands listed below and fluorescenceintensity or reaction rate as determined using standards according toExamples 1-7 and 9-14, respectively, for use as standard curves inassays for the various ligands.

    ______________________________________                                        FIG.             Ligand Assayed                                               ______________________________________                                         4               Gentamicin                                                   5                Sisomicin                                                    6                Netilmicin                                                   7                Tobramycin                                                   8                Kanamycin                                                    9                Amikacin                                                     10               Diphenylhydantoin                                            11               Phenobarbital                                                12               Theophylline                                                 13               Carbamazepine                                                14               Primidone                                                    15               IgG                                                          ______________________________________                                    

Tables A through F are flow diagrams of synthetic schemes described inthe examples.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the context of this disclosure, the following terms shall be definedas follows: "ligand" is the substance, or class of related substances,whose presence or the amount thereof in a liquid medium is to bedetermined; "specific binding partner of the ligand" is any substance,or class of substances, which has a specific binding affinity for theligand to the exclusion of other substances; "specific binding analog ofthe ligand" is any substance, or class of substances, which behavesessentially the same as the ligand with respect to the binding affinityof the specific binding partner for the ligand; "monitoring reaction" isthe reaction in which the glycosidic linkage in the labeled conjugate iscleaved enzymatically to release a detectable indicator product; "loweralkyl" is an alkyl group comprising from 1 to 6 carbon atoms, inclusive,such as methyl, ethyl, isopropyl, and hexyl.

LABEL RESIDUE

In the novel label residue of the present invention, the glycone may beany group which constitutes the carbohydrate portion of a glycoside. Ingeneral, therefore, the glycone is a sugar residue bound through anacetal linkage to the dye indicator moiety in the labeled conjugate. Thesugar residue may be selected from residues of monosaccharides,including the aldo-, keto-, deoxy-, and derivatized forms of thetrioses, tetroses, pentoses, hexoses and heptoses in their D- orL-stereoisomeric forms; oligosaccharides, such as disaccharides andtrisaccharides; and polysaccharides. Where the acetal linkage to the dyeindicator moiety is adjacent to an anomeric carbon in the glycone, boththe α- and β-stereoconfigurations may be used. It is preferred that theglycone be a monosaccharide such as a pentose, e.g., ribose, arabinose,xylose, and lyxose, with hexoses being particularly preferred, e.g.,galactose, glucose, mannose, and gulose. Derivatized monosaccharideresidues which may be used include, without limitation,amino-substituted sugars, e.g., glucosamine and galactosamine, O-acyland O-methyl derivatives, and glucuronides. It is contemplated thatoligo- and polysaccharides and their derivatives may be used as well,e.g., the disaccharide cellobiose.

The most preferred group from which the glycone is selected consists ofgalactosyl, particularly α- and β-D-galactosyl; glucosyl, particularlyα- and β-D-glucosyl; N-acetyl-galactosaminyl, particularly N-acetyl-α-or N-acetyl-β-D-galactosaminyl; N-acetyl glucosaminyl, particularlyN-acetyl-α- and N-acetyl-β-glucosaminyl; glucuronyl, particularlyβ-D-glucuronyl; arabinosyl, particularly α-L-arabinosyl; fucosyl,particularly β-L-fucosyl; mannosyl, particularly α-D-mannosyl; andxylosyl, particularly β-D-xylosyl. The most preferred glycone is aβ-galactosyl group.

DYE INDICATOR MOIETY

With regard to the dye indicator moiety in the novel label residue ofthe present invention, this moiety may comprise any constituent, usuallyone containing an organic nucleus especially of aromatic character,couplable to the glycone through a glycosidic linkage and to the bindingcomponent of the labeled conjugate through a suitable linking group,such that upon cleavage of such glycoside linkage by an enzymeappropriate for the glycone, there results a detectable dye productdistinguishable from the intact labeled conjugate. Preferably the dyeindicator moiety is of a type such that the detectable dye product ofthe enzymatic cleavage is fluorometrically or colorimetrically active.The desired distinctive indicator property of the cleaved product isobtained, in general, by linking the glycone and the dye indicatormoiety at a site on the nucleus of the latter such that the fluorogenicor chromogenic character of the cleaved dye product is distinct fromthat of the intact labeled conjugate. For example, the fluorogenic andchromogenic characters of many known aromatic dyes can be altered bymodifying an aryl hydroxyl group. Such a group provides an availablesite for linkage to the glycone through a glycosidic linkage which uponenzymatic cleavage results in release of a dye product having afluorogenic or chromogenic character similar to that of the aromatic dyebefore formation of the labeled conjugate. Usually the fluorescencespectrum of the dye indicator moiety in the labeled conjugate will beshifted from that of the aromatic dye itself. The cleavage reaction isshown schematically below wherein ##STR1## would represent the sugarprecursor of the glycone with only the anomeric hydroxyl groupspecifically shown, A is an aryl nucleus, R is the linking group and Lis the binding component of the labeled conjugate: ##STR2##

Examples of dyes useful for incorporation into the labeled conjugate ofthe present invention as the dye indicator moiety are umbelliferone,fluorescein, naphthol, indole, pyridol and resorufin, and activederivatives thereof. Following in Table 1 are representative labeledconjugates comprising residues of such dyes which are contemplated foruse in the present invention G(O-- represents the glycone terminating ina bridging oxygen atom which forms a part of the acetal linkage with thedye indicator moiety and --R--L represents a linking group and thelinked binding component for the conjugate.

                  TABLE 1                                                         ______________________________________                                        dye residue     structural formula                                            ______________________________________                                        umbelliferone [wherein one of R.sup.1 and R.sup.2 is RL and the other is      hydrogen or methyl]                                                                            ##STR3##                                                     fluorescein [wherein R.sup.3 is hydroxyl or (O)G]                                              ##STR4##                                                     3-indole                                                                                       ##STR5##                                                     naphthol                                                                                       ##STR6##                                                     pyridol                                                                                        ##STR7##                                                     resorufin                                                                                      ##STR8##                                                     ______________________________________                                    

Other variations of labeled conjugates based on the above listed dyeresidues are clearly evident. Various derivatives, particularly in thenature of aryl substituted derivatives, which retain sufficient abilityto be coupled to the glycone and binding component and to exhibitappropriate fluorogenic or chromogenic character in the cleavedindicator product can be used in preparing labeled conjugates. Labeledconjugates which are prepared using such a substituted dye as startingmaterial will possess substantially the same properties as theconjugates prepared from the above-listed dyes. Such conjugates will berecognized as equivalents and are exemplified by addition of one, two ormore simple substituents to an available aromatic ring site, suchsubstituents including without limitation lower alkyl, e.g., methyl,ethyl and butyl; halo, e.g., chloro and bromo; nitro; carboxyl; carbolower alkoxy, e.g., carbomethoxy and carbethoxy; amino; mono- anddi-lower alkylamine, e.g., methylamino, dimethylamino andmethylethylamino; amido; hydroxyl; lower alkoxy, e.g., methoxy andethoxy; and so forth.

The preferred dye indicator moiety is an umbelliferone residue which isbound directly to the glycone by an acetal linkage at the 7-position andbound to the binding component through a linking group at the 3 or4-position, preferably the former. Especially useful are labeledconjugates comprising such an umbelliferone residue coupled to aβ-galactosyl group as the glycone at the 7-position and to the bindingcomponent through the 3-position. Such conjugates are represented as:##STR9## wherein R is a linking group and L is the binding componentsuch as a hapten of molecular weight between 100 and 1000 or anantigenic protein or polypeptide of molecular weight between 1,000 and10,000,000.

LINKING GROUP

It will be recognized that there are many methods available for linkingthe binding component of the labeled conjugate, e.g., the ligand to bedetected, a binding analog thereof, or a binding partner thereof, to thedye indicator moiety. The particular chemical character of the linkinggroup will depend upon the nature of the respective available linkingsites on the binding component and the dye indicator moiety. Theimportant considerations in selecting the linking sites are (1)preservation of the ability of the linked binding component toparticipate effectively in the selected binding assay system and (2)preservation of the ability of the linked dye indicator moiety uponenzymatic cleavage to yield an effectively detectable product, in bothcases, to the extent that a useful assay will result for the particularligand under assay and for the particular concentrations or amounts inwhich such ligand is to be detected. Usually the linking group willcomprise a chemical bond, usually a single, but sometimes a double bond,or a chain containing between 1 to 10, more commonly 1 to 6, carbonatoms and 0 to 5, more commonly 1 to 3, heteroatoms selected fromnitrogen, oxygen, and sulfur.

Both the dye indicator moiety and the binding component, of course, willoffer a great diversity of available functionalities for attachment ofthe linking group. Commonly the functionalities that can be expected tobe available to the linking group are amines, usually amino; hydroxyl;halo, usually chloro or bromo; carboxylic acid; aldehyde; keto;isothiocyanate; isocyanate; and so forth. Accordingly, the chemicalstructure of the linking group itself will vary widely with its terminalgroups depending on the functionalities available on the dye indicatormoiety and the binding component and its overall length being a matterof choice within the basic constraint of maintaining the essentialenzymatic substrate and binding component characters of the resultingconjugate. With regard to the length of the linking group in preparing aconjugate for use in a homogeneous assay format, it is usually desirableto use as short a group as possible without causing the resultingbinding component in the conjugate to interfer significantly with thesubstrate activity of the conjugate. Where the binding component is oflow molecular weight (e.g., a hapten of molecular weight between 100 and1000), the linking group is preferably a chemical bond or a 1 to 3 atomchain such as carbonyl, amido, and the like. In other circumstances,such as where the binding component in the conjugate is of relativelyhigh molecular weight, such as a polypeptide or protein (e.g., anantibody), a longer linking group is usually desirable to prevent sterichindrance of the substrate-active site of the conjugate. In these cases,the linking group will comprise usually 4 to 10 carbon atoms and 0 to 5heteroatoms as previously discussed. Chains of any significantly greaterlength will tend to result in conjugates in which the binding componentwill tend to fold-back into the substrate-active site. With theseconsiderations in mind, examples of linking groups are shown in Table 2.Particular examples of linking groups will be seen hereinafter andfurther variations will be readily recognized as being state-of-the-art.

                  TABLE 2                                                         ______________________________________                                        linking group                                                                 ______________________________________                                         ##STR10##                                                                     ##STR11##                                                                     ##STR12##                                                                    ______________________________________                                    

wherein X is imino, sulfur or, preferably, oxygen; and R⁴ and R⁵ are,independently, a bond or lower alkylene such as methylene, ethylene,butylene or hexylene.

The present assay can be applied to the detection of any ligand forwhich there is a specific binding partner. The ligand usually is apeptide, protein, carbohydrate, glycoprotein, steroid, or other organicmolecule for which a specific binding partner exists in biologicalsystems or can be synthesized. The ligand, in functional terms, isusually selected from the group consisting of antigens and antibodiesthereto; haptens and antibodies thereto; and hormones, vitamins,metabolites and pharmacological agents, and their receptors and bindingsubstances. Specific examples of ligands which can be detected using thepresent invention are hormones such as insulin, chorionic gonadotropin,thyroxine, liothyronine, and estriol; antigens and haptens such asferritin, bradykinin, prostaglandins, and tumor specific antigens;vitamins such as biotin, vitamin B₁₂, folic acid, vitamin E, vitamin A,and ascorbic acid; metabolites such as 3', 5' adenosine monophosphateand 3', 5' guanosine monophosphate; pharmacological agents or drugs,particularly those described below; antibodies such as microsomalantibody and antibodies to hepatitis and allergens; and specific bindingreceptors such as thyroxine binding globulin, avidin, intrinsic factor,and transcobalamin. The present assay is particularly useful for thedetection of haptens, and analogs thereof, of molecular weight between100 and 1000, particularly drugs and their analogs, including theaminoglycoside antibiotics such as streptomycin, neomycin, andespecially gentamicin, tobramycin, amikacin, kanamycin, sisomicin, andnetilmicin; anticonvulsants such as diphenylhydantoin, phenobarbital,primidone, carbamazepine, ethosuximide, and sodium valproate;bronchodialators such as theophylline; cardiovascular agents such asquinidine, procainamide and propranolol; drugs of abuse such asmorphine, barbiturates and amphetamines; tranquilizers such as valiumand librium; and various other drugs, including amitriptyline, cortisol,cyclophosphamide, desipramine, disopyramide, doxepin, doxorubicin,imipramine, lidocaine, methotrexate and nortriptyline.

As stated previously, the present assay method can follow, inappropriate circumstances, either a homogeneous or a heterogeneousscheme.

HOMOGENEOUS SCHEMES

A homogeneous scheme, i.e., one which does not require a physicalseparation of the bound-species and the free-species, is available wherereaction between the binding component of the labeled conjugate and acorresponding binding partner causes a measurable change, either in apositive or a negative sense, in the ability of the label component ofthe labeled conjugate to participate in the monitoring reaction, i.e.,in the ability of the labeled conjugate to be cleaved enzymatically torelease the detectable product. In such a case, the distribution of thelabel component between the bound-species and the free-species can bedetermined by adding the enzyme directly to the binding reaction mixtureand measuring therein the activity of the substrate-active labelcomponent, i.e., the rate or total amount of detectable product thatresults, which preferably comprises measuring the rate of fluorescenceor color production or the total amount thereof produced. Severalmanipulative schemes are available for carrying out a homogeneous assaywith preference being given to the direct binding and competitivebinding techniques.

Briefly, in the direct binding technique, a liquid medium suspected ofcontaining the ligand to be detected, usually a compound of highmolecular weight (e.g., an antibody) relative to a selected bindingpartner (e.g., an antigen or hapten), is contacted with the presentlabeled conjugate in which the binding component is the selectedspecific binding partner of the ligand, and thereafter any change in thesubstrate activity of the label component is assessed. In thecompetitive binding technique, primarily useful for the detection of acompound of low molecular weight (e.g., an antigen or hapten) relativeto a selected binding partner (e.g., an antibody), the liquid medium iscontacted with the selected specific binding partner of the ligand andwith the present labeled conjugate in which the binding component is oneof the ligand or a specific binding analog thereof, and thereafter anychange in the substrate activity of the label component is assessed. Inboth techniques, the substrate activity of the label component isdetermined by contacting the liquid medium with an enzyme which cancleave the glycosidic linkage in the label component of the free-speciesform of the labeled conjugate and then measuring the rate or amount ofdetectable product which results. Qualitative determination of theligand in the liquid medium involves comparing a characteristic, usuallythe rate, of the resulting reaction to that of the monitoring reactionin a liquid medium devoid of the ligand, any difference therebetweenbeing an indication of the presence of such ligand in the liquid tested.Quantitative determination of the ligand in the liquid medium involvescomparing a characteristic of the resulting reaction to that of themonitoring reaction in liquid media containing various known amounts ofthe ligand, e.g., a comparison to a standard curve.

A schematic representation of the principles of a competitive bindingtype of homogeneous immunoassay for a drug is shown in FIG. 1 of thedrawing. As shown, the free labeled drug is acted upon the enzyme torelease a fluorescent product. However, upon addition of antibody to thedrug, the action of the enzyme on the resulting labeled drug-antibodycomplex is inhibited, probably by steric hindrance. In the competitivebinding reaction then, the ability of the enzyme to release thefluorescent product is dependent upon the ratio of labeled drugremaining free to that bound to antibody. Thus, the reaction rate ofproduction of fluorescence is proportional to the amount of drug to beassayed which competes with labeled drug for antibody binding.

In general, when following a homogeneous assay scheme, the components ofthe specific binding reaction, i.e., the liquid medium suspected ofcontaining the ligand, the labeled conjugate, and, in some systems, aspecific binding partner of the ligand, may be combined in any amount,manner, and sequence, provided that the activity of the label componentof the labeled conjugate is measurably altered when the liquid mediumcontains the ligand in an amount or concentration of significance to thepurposes of the assay. Preferably, all of the components of the specificbinding reaction are soluble in the liquid medium.

Known variations of the above briefly described homogeneous methods andfurther details concerning the specific techniques discussed are readilyavailable in the literature, e.g., German OLS No. 2,618,511,corresponding to U.S. Patent Application Ser. No. 667,996, filed Mar.18, 1976, now abandoned, and assigned to the present assignee.

HETEROGENEOUS SCHEMES

The use of the present novel substrate-active labels can also be appliedto the conventional heterogeneous type assay schemes wherein the bound-and free-species of the labeled conjugate are separated and the quantityof label in one or the other is determined. The reagent means forperforming such a heterogeneous assay can take on many different forms.In general, such means comprises three basic constituents, which are (1)the ligand to be detected, (2) a specific binding partner of the ligand,and (3) the labeled conjugate. The binding reaction constituents arecombined simultaneously or in a series of additions, and with anappropriate incubation period or periods, the labeled conjugate becomesbound to its corresponding binding partners such that the extent ofbinding, i.e., the ratio of the amount of labeled conjugate bound to abinding partner (the "bound-species") to that unbound (the"free-species"), is a function of the amount of ligand present. Thebound- and free-species are physically separated and the amount of labelpresent in one thereof is compared to a negative control or standardresults, e.g., a standard curve.

Various means of performing the separation step and of forming thebinding reaction systems are available in the art. Separation caninvolve such conventional techniques as those involving what is commonlyknown as a solid-phase antibody or antigen, a second antibody, or asolid phase second antibody, as well as the use of immune complexprecipitating agents and adsorbents, and so forth. Binding reactionsystems that can be followed include the so-called competitive bindingtechnique, the sequential saturation technique, the "sandwich"technique, and so forth. Further details concerning the various knownheterogeneous systems are readily available in the literature, e.g.,German OLS No. 2,618,419, corresponding to U.S. Patent Application Ser.No. 667,982, filed Mar. 18, 1976, now abandoned, and assigned to thepresent assignee.

It should be recognized that manipulative schemes involving other ordersof addition and other binding reaction formats can be devised forcarrying out homogeneous and heterogeneous specific binding assayswithout departing from the inventive concept embodied herein.

The liquid medium to be tested can be a naturally occurring orartifically formed liquid suspected of containing the ligand, andusually is a biological fluid or a liquid resulting from a dilution orother treatment thereof. Biological fluids which can be assayedfollowing the present method include serum, plasma, urine, saliva, andamniotic, cerebral, and spinal fluids. Other materials such as solidmatter, for example tissue, or gases can be assayed by reducing them toa liquid form such as by dissolution of the solid or gas in a liquid orby liquid extraction of the solid.

In general, in those instances where for purposes of a selected bindingassay system the binding component in the labeled conjugate is theligand or an analog thereof, the present labeled conjugate can be termeda glycone-dye-labeled ligand and can be represented by the formula:

    G-D-R-L

wherein G, D and R have their meanings as hereinabove and L is theligand or analog thereof, usually a hapten or an antigenic protein orpolypeptide. A polypeptide is conventionally defined as a polymer ofamino acids joined by amide linkages, forming chains that can consist ofas few as two or as many as several thousand amino acid residues.

As discussed previously herein, the preferred labeled conjugatescomprise an umbelliferone residue coupled to a β-galactosyl group by anacetal linkage at the 7-position and bound to the binding componentthrough the 3-position. In the usual case, the binding component will bea hapten, usually of molecular weight between 100 and 1,000, or anantigenic protein or polypeptide, usually of molecular weight between1,000 and 10,000,000. Such hapten or antigenic protein or polypeptidewill be a ligand of clinical interest, whereby the label component isbound directly thereto, or a derivative of a ligand of clinicalinterest, whereby the label component is bound through a bridge group.

The preferred β-galactosyl-umbelliferone labeled conjugates are preparedby first obtaining the intermediate of the formula: ##STR13## wherein Zis hydrogen or a suitable salt cation such as potassium or sodium, byreaction of 3-carboethoxyumbelliferone and tetraacetyl-α-D-galactosylbromide followed by hydrolysis according to the method of Leaback, Clin.Chem. Acta 12:647(1965). The compound to be labeled (either the ligandof analytical interest or a derivative thereof) is selected to have anamino or carboxyl group available for coupling to the β-GUA intermediateby formation of a peptide or amide bond.

Condensation of the β-GUA intermediate to the compound to be labeled canbe accomplished by reacting the β-GUA intermediate directly with anamino group-containing ligand or derivative thereof using conventionalpeptide condensation reactions such as the carbodiimide reaction[Science 144:1344(1964)], the mixed anhydride reaction [Erlanger et al,Methods in Immunology and Immunochemistry, ed. Williams and Chase,Academic Press (New York 1967) p. 149], and the acid azide and activeester reactions [Kopple, Peptides and Amino Acids, W. A. Benjamin, Inc.(New York 1966)]. See also for a general review Clin. Chem.22:726(1976).

It will be recognized, of course, that other well known methods areavailable for coupling the compound to be labeled to the β-GUAintermediate. In particular, conventional bifunctional coupling agentscan be employed for coupling a ligand, or its derivative, containing acarboxylic acid or amino group to the β-GUA intermediate. For example,appropriate coupling reactions are well known for inserting a bridgegroup in coupling an amine to a carboxylic acid. Coupling reactions ofthis type are thoroughly discussed in the literature, for instance inthe above-mentioned Kopple monograph and in Lowe & Dean, AffinityChromatography, John Wiley & Sons (New York 1974). Such couplingtechniques will be considered equivalents to the previously discussedpeptide condensation reactions in preparing useful labeled conjugates.The choice of coupling technique will depend on the functionalitiesavailable in the compound to be labeled for coupling to the β-GUAintermediate and on the length of bridging group desired.

General methods for coupling antigenic proteins and polypeptides andhaptens to the β-GUA intermediate will now be described.

Proteins and Polypeptides

The β-galactosyl-umbelliferone-labeled conjugates will have the formula:##STR14## wherein --NH)L is an antigenic protein or polypeptide boundthrough an amide bond and p=1 to the number of available amino groups inL.

Representative of specifically bindable protein ligands are antibodiesin general, particularly those of the IgG, IgE, IgM and IgA classes, forexample hepatitis antibodies; and antigenic proteins such as insulin,chorionic gonadotropin (e.g., HCG), carcinoembryonic antigen (CEA),myoglobin, hemoglobin, follicle stimulating hormone, human growthhormone, thyroid stimulating hormone (TSH), human placental lactogen,thyroxine binding globulin (TBG), instrinsic factor, transcobalamin,enzymes such as alkaline phosphatase and lactic dehydrogenase, andhepatitis-associated antigens such as hepatitis B surface antigen(HB_(s) Ag), heptatitis B e antigen (HB_(e) Ag) and hepatitis B coreantigen (HB_(c) Ag). Representative of polypeptide ligands areangiotensin I and II, C-peptide, oxytocin, vasopressin, neurophysin,gastrin, secretin, and glucagon.

Since, as peptides, ligands of this general category possess numerousavailable carboxylic acid and amino groups, coupling to the β-GUAintermediate can proceed according to conventional peptide condensationreactions such the carbodiimide reaction, the mixed anhydride reaction,and so forth as described hereinabove, or by the use of conventionalbifunctional reagents likewise as described above. General referencesconcerning the coupling of proteins to primary amines or carboxylicacids are mentioned in detail above.

Haptens

The β-galactosyl-umbelliferone-labeled conjugates will have the formula:##STR15## wherein --NH)L is a hapten bound through an amide bond.

Haptens, as a class, offer a wide variety of organic substances whichevoke an immunochemical response in a host animal only when injected inthe form of an immunogen conjugate comprising the hapten coupled to acarrier molecule, almost always a protein such as albumin. The couplingreactions for forming the immunogen conjugates are well developed in theart and in general comprise the coupling of a carboxylic acid or aminogroup-containing hapten or a carboxylic acid or amino derivative of thehapten to available amino or carboxylic acid groups on the proteincarrier by formation of an amide bond. Such well known couplingreactions are directly analogous to the present formation of labeledconjugates by coupling carboxylic acid or amino group-containing haptensor hapten derivatives to the β-GUA intermediate.

Hapten ligands which themselves contain amino functions, and whichthereby can be coupled directly to the β-GUA intermediate, include theiodothyronine hormones such as thyroxine and liothyronine, as well asother materials such as aminoglycoside antibiotics. Following arerepresentative synthetic routes for preparing carboxylic acid and amineanalogs of haptens of analytical interest which themselves do notcontain an available carboxylic acid or amino function whereby suchanalogs can be coupled to the β-GUA intermediate by the aforementionedpeptide condensation reactions or bifunctional coupling agent reactions(in the structural formulae below, n represents an integer, usually 1through 6, and Me represents methyl).

Carbamazepine

Dibenz[b,f]azepine is treated sequentially with phosgene, anω-aminoalkanol, and Jones reagent (chromium trioxide in sulfuric acid)according to the method of Singh, U.S. Pat. No. 4,058,511 to yield aseries of carboxylic acids (R*=COOH). The corresponding primary amines(R*=NH₂) are obtained by treating dibenz[b,f]azepine sequentially withphosgene and an α,ω-diaminoalkane. ##STR16##

Quinidine

Following the method of Cook et al, Pharmacologist 17:219(1975),quinidine is demethylated and treated with ethyl 5-bromovaleratefollowed by acid hydrolysis to yield a suitable carboxylic acidderivative. The corresponding primary amines can be obtained by any ofthe conventional methods for converting carboxyl groups to amino groupssuch as the Hofmann reaction, the Schmidt reaction, and the Curtiusreaction [Organic Reactions, vol. III, ed. Adams et al, Robert E.Kreiger Publishing Co., Huntington, NY (1975)]. Useful amine derivativescan also be prepared by reacting the carboxylic acid derivative withα,ω-diaminoalkanes to yield ω-aminoalkylamides.

Digoxin and Digitoxin

The aglycone of the cardiac glycoside is treated with succinic anhydrideand pyridine according to the method of Oliver et al, J. Clin. Invest.47:1035(1968) to yield a suitable carboxylic acid (R*=COOH). Suitableprimary amines R*=NH₂) are obtained by the aforesaid techniques, i.e.,the Hofmann, Schmidt, and Curtius reactions or formation ofω-aminoalkylamides. ##STR17##

Theophylline

Following the method of Cook et al, Res. Comm. Chem. Path. Pharm13:497(1976), 4,5-diamino-1,3-dimethylpyrimidine-2,6-dione is heatedwith glutaric anhydride to yield a suitable carboxylic acid (R*=COOH).Suitable primary amines (R*=NH₂) are obtained by the aforesaidtechniques (cf. Example 9). ##STR18##

Phenobarbital and Primidone

Sodium phenobarbital is heated with methyl 5-bromovalerate and theproduct hydrolyzed to the corresponding acid derivative (R*=COOH) ofphenobarbital [Cook et al, Quantitative Analytic Studies in Epilepsy,ed. Kelleway and Peterson, Raven Press (New York 1976) pp. 39-58].Suitable primary amines (R*=NH₂) are obtained by the aforesaidtechniques. ##STR19##

To obtain the acid derivative of primidone following the same Cook et alreference method, 2-thiophenobarbital is alkylated, hydrolyzed, and theproduct treated with Raney nickel to yield a suitable carboxylic acid(R*=COOH). Again, suitable primary amines (R*=NH₂) are obtained by theaforesaid techniques. ##STR20##

Diphenylhydantoin

Following the method of Cook et al, Res. Comm. Chem. Path. Pharm.5:767(1973), sodium diphenylhydantoin is reacted with methyl5-bromovalerate followed by acid hydrolysis to yield a suitablecarboxylic acid (R*=COOH). Suitable primary amines (R*=NH₂) are obtainedby the aforesaid techniques. ##STR21##

Morphine

Morphine free base is treated with sodium β-chloroacetate according tothe method of Spector et al, Science 168:1347(1970) to yield a suitablecarboxylic acid derivative. The corresponding primary amine is obtainedby the aforesaid techniques.

Nicotine

According to the method of Langone et al, Biochem 12(24):5025(1973),trans-hydroxymethylnicotine and succinic anhydride are reacted to yielda suitable carboxylic acid (R*=COOH). Suitable amines (R*=NH₂) areobtained by the aforesaid techniques. ##STR22##

Androgens

Suitable carboxylic acid derivatives (R*=COOH) of testosterone andandrostenedione linked through either the 1- or 7-position on thesteroid nucleus are prepared according to the method of Bauminger et al,J. Steroid Biochem. 5:739(1974). Suitable amines (R*=NH₂) are obtainedby the aforesaid techniques. ##STR23##

Estrogens

Suitable carboxylic acid derivatives (R*=COOH) of estrogens, e.g.,estrone, estradiol and estriol, are prepared according to the method ofBauminger et al, supra. Suitable amines (R*=NH₂) are obtained by theaforesaid techniques. ##STR24##

Progesterones

Suitable carboxylic acid derivatives (R*=COOH) of progesterone and itsmetabolites linked through any of the 3-, 6- or 7-positions on thesteroid nucleus are prepared according to the method of Bauminger et al,supra. Suitable amines (R*=NH₂) are obtained by the aforesaidtechniques. ##STR25##

The methods described above are but examples of the many knowntechniques for forming suitable carboxylic acid and amine derivatives ofhaptens of analytical interest. The principal derivation techniques forpreparing the acids are discussed in Clin. Chem. 22:726(1976) andinclude esterification of a primary alcohol with succinic anhydride[Abraham and Grover, Principles of Competitive Protein-Binding Assays,ed. Odell and Daughaday, J. B. Lippincott Co. (Philadelphia 1971) pp.140-157], formation of an oxime from reaction of a ketone group withcarboxylmethyl hydroxylamine [J. Biol. Chem. 234:1090(1959),introduction of a carboxyl group into a phenolic residue usingchloroacetate [Science 168:1347(1970)], and coupling to diazotizedp-aminobenzoic acid in the manner described in J. Biol. Chem.235:1051(1960). The corresponding amines are prepared by any of theconventional methods (i.e., the Hofmann, Schmidt, and Curtius reactions,supra) or by reacting the carboxylic acid derivatives withα,ω-diaminoalkanes to yield ω-aminoalkylamides.

The present invention will now be illustrated, but is not intended to belimited by, the following examples.

    ______________________________________                                        TABLE OF CONTENTS FOR EXAMPLES                                                Example No.                                                                              Ligand Assayed  Assay Type                                         ______________________________________                                        1          Gentamicin      Rate/Fixed-Time                                    2          Sisomicin       Rate                                               3          Netilmicin      Rate                                               4          Tobramycin      Rate                                               5          Kanamycin       Rate                                               6          Amikacin        Rate                                               7          Diphenylhydantoin                                                                             Rate                                               8          Aminoglycosides Fixed-Time                                         9          Phenobarbital   Fixed-Time                                         10         Theophylline    Fixed-Time                                         11         Carbamazepine   Fixed-Time                                         12         Primidone       Fixed-Time                                         13         Immunoglobulins Fixed-Time                                         ______________________________________                                    

EXAMPLES 1-6 Aminoglycoside Antibiotic Assays

To perform an assay for an aminoglycoside antibiotic according to thepresent invention there can be used a labeled conjugate wherein thebinding component is said antibiotic under assay or a binding analogthereof. Where an antibody is used as binding partner in the assay, suchas in a homogeneous or heterogeneous competitive binding assay, it hasbeen found that other aminoglycoside antibiotics can cross-react withthe antibody for the antibiotic under assay. Thus such other antibioticsqualify as binding analogs and could be used to form the labeledconjugate. Further, the antibody qualifies as reagent for use in assaysfor the cross-reacting antibiotic. For example, in an assay forgentamicin it has been found that with appropriate antiserum the bindingcomponent in the labeled conjugate can be gentamicin itself or sisomicinwhich cross-reacts. Thus, gentamicin antiserum and a labeled sisomicinconjugate could be used in an assay for gentamicin. Specificity problemsare not encountered in clinical situations because it would be knownwhat antibiotic was administered and only one aminoglycoside antibioticis administered at a time.

The β-galactosyl-umbelliferone-labeled conjugates formed are of theformula: ##STR26## wherein R is a linking group as describedhereinbefore terminating in an amino-linking group, preferably carbonyl;L is an aminoglycoside antibiotic selected from the group consisting ofgentamicin, tobramycin, amikacin, kanamycin, sisomicin, and netilmicin,coupled by a covalent bond to the linking group R through a primaryamino group therein; and n equals 1 to the total number of primary aminogroups in the selected antibiotic, inclusive.

EXAMPLE 1 Gentamicin Assays A. Preparation of glycone-dye-drug conjugate

The reaction sequence for the preparation of the glycone-dye-drugconjugate is given in Table A in the drawings.3-carboethoxy-7-hydroxycoumarin (II) was prepared by a Knoevenagelcondensation of 2,4-dihydroxybenzaldehyde (Aldrich Chemical Co.,Milwaukee, Wisconsin, USA) with diethylmalonate in acetic acid, benzene,and piperidine as described in J. Am Chem. Soc. 63:3452(1971). Thepotassium salt of 7-β-galactosylcoumarin-3-carboxylic acid (III) wasprepared by the reaction of 3-carboethoxy-7-hydroxycoumarin (II) and2,3,4,6-tetraacetyl-α-D-galactosyl bromide (I, Sigma Chemical Co., St.Louis, Missouri, USA) as described by Leaback for the preparation ofmethylumbelliferyl-β-D-galactoside in Clin. Chim. Acta 12:647(1965). Thepotassium salt of this compound was purified by chromatography on silicagel-60 (E. Merck, St. Louis, Missouri, USA) with a gradient ofn-butanol/methanol/water (4/2/1 by volume) and methanol/water (1/6).After recrystallization from acetone-water, the corrected melting pointof the product was 258°-263° C. (decomp.).

Analysis: Calculated for C₁₆ H₁₅ O₁₀ K: C, 47,28; H, 3.73; K, 9.62.Found: C, 47.30; H, 3.74; K, 9.34.

[α]_(D) =-77.4° (c 1.0, H₂ O).

NMR Spectrum (D₂ O): δ8.2 (s, 1H), 7.6 (m, 1H), 7.0 (m, 2H), 5.1 (s,1H), and 4.0 (m, 6H).

Infrared Spectrum (KBr): 1705 cm⁻¹ (carbonyl), 1620 cm⁻¹ (C═C).

β-Galactosyl-umbelliferone-sisomicin (IV) was prepared by mixing 50milligrams (mg) (117 μmol) of the potassium salt of7-β-galactosylcoumarin-3-carboxylic acid (III) with 171 mg of sisomicinsulfate (223 μmol of sisomicin free base, Schering Corp., Bloomfield,N.J., U.S.A.) in 2 ml of water. The pH was adjusted to 3.8 by dropwiseaddition of 1 molar hydrochloric acid. The solution was cooled in an icebath and 30 mg (150 μmol) of1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (PierceChemical Co., Rockford, Illinois, U.S.A.) was added. After 2 hours themixture was chromatographed at 25° C. on a 2.5×50 centimeter (cm) columnof CM-Sephadex C-25 (Pharmacia Laboratories, Inc., Piscataway, N.J.U.S.A.) 5.8 ml fractions were collected, and their absorbance wasmonitored at 345 nanometers (nm). The column was washed with 200 ml of50 mmol/liter ammonium formate to elute unreacted7-β-galactosylcoumarin-3-carboxylic acid (III). A linear gradient formedwith 400 ml of 50 mmol/liter and 400 ml of 1.8 mol/liter ammoniumformate, was applied to the column. A peak of material absorbing at 345nm eluted at approximately 1.4 mol/liter ammonium formate. After thegradient, the column was washed with 600 ml of 1.8 mol/liter ammoniumformate. Three 345 nm absorbing peaks were eluted in this wash. Elutedunreacted sisomicin was well separated from the last 345 nm absorbingpeak.

The carbodiimide-activated reaction leads to the formation of amidebonds between the carboxylic acid ofβ-[7-(3-carboxycoumarinoxy)]-galactoside and the primary amino groups ofsisomicin. The major peak of β-galactosyl-umbelliferonesisomicin (thelast 345 nm absorbing peak) was used in the present stuides. Ammoniumformate was removed by lyophilization. Because the absorptivity ofisolated labeled conjugate is currently unknown, the relativeconcentration is presented in terms of A₃₄₅ units. One A₃₄₅ unit is thequantity of material contained in 1 ml of a solution that has anabsorbance of 1.0 at 345 nm when measured with a 1 cm light path.

B. Assay Procedure--Rate Assay

The principle of the assay is shown schematically in FIG. 1 of thedrawings.

A reagent, prepared in 50 mmol/liter N,N-bis-(2-hydroxyethyl)-glycine(Bicine) buffer (pH 8.2, Nutritional Biochemicals Corp., Cleveland,Ohio, U.S.A.), contained β-galactosidase (25 ng protein/ml, Escherichiacoli--derived enzyme, Grade IV, Sigma Chemical Co., St. Louis, Missouri,U.S.A.) and antiserum to gentamicin (prepared as described in Nature NewBiol. 239:214(1972) in an amount sufficient to decrease the reactionrate in the final reagent to 20 to 30% of the rate observed in theabsence of antibody). One unit (U) of the enzyme was defined as thatamount which hydrolyzed 1.0 μmole of o-nitrophenyl-β-D-galactoside perminute at pH 7.2 at 37° C. The enzyme preparation used had a specificactivity of 745 U per milligram of protein.

To 2.0 ml aliquots of the reagent in a cuvette were added 1 μl aliquotsof serum standards or unknown. After mixing, 5 μl of an aqueous solutionof the labeled conjugate prepared in part A (0.125 A₃₄₅ units per ml)was added to each cuvette and the rate of increase in fluorescence wasmonitored in each for 2 to 3 minutes. All solutions were kept at 25° C.,except the labeled conjugate which was kept in an ice bath.

C. Results--Rate Assay

The absorbance spectrum of the labeled conjugate,β-galactosyl-umbelliferone-sisomicin, showed an absorbance maximum at345 nm. When the conjugate was hydrolyzed with bacterial β-galactosidaseto remove the galactose moiety, the absorbance at 345 nm decreased and anew maximum appeared at 402 nm. The absorbance of the enzyme-treatedconjugate was 1.46 times that of the untreated conjugate.

Analysis of the fluorescence spectrum of the conjugate revealed asimilar shift in the maximum wavelength. Before enzyme treatment, theconjugate exhibited excitation and emission maxima at 350 and 394 nm,respectively. After hydrolysis with β-galactosidase, a 15-fold increasein fluorescence was observed, with new excitation and emission maxima of409 and 445 nm, respectively. Hence, under the conditions of thefluorescent assay (excitation and emission wavelengths of 400 and 453)the unreacted conjugate contributed negligible fluorescence. For all ofthe aminoglycoside antibiotic assays reported herein, the excitation andemission wavelengths used in the fluorometric measurements wereapproximately 400 and 450 nm, respectively.

The effect of antiserum to gentamicin on the ability of the labeledconjugate to function as a substrate for β-galactosidase was examined.Various amounts of antiserum were added to 2.0 ml of bufferedβ-galactosidase. The labeled conjugate was added and the reaction ratedetermined using an Aminco-Bowman Spectrofluorometer connected to astrip-chart recorder. Reaction rates are expressed in terms of recorderunits/minute. As the amount of antiserum increased, the reaction ratedecreased as shown in FIG. 2 of the drawings. Based upon thisexperiment, an amount of antiserum sufficient to inhibit the reactionrate by 70 to 80% was chosen for the competitive binding reactions. Thereaction between the antibody and the conjugate appeared to be completein the time required for mixing the reagents, because incubation of theconjugate with the antibody before adding enzyme did not alter theresults.

For the standard curve, gentamicin standards were prepared from 0 to 14μg/ml (mg/liter) in normal human serum and assayed as described in partB above. FIG. 3 of the drawings shows the standard curve of the reactionrate related to gentamicin concentration in serum standards. Reactionrate was calculated for each standard as the percentage of the maximumreaction rate in the absence of antiserum, after substraction offluorescence in the absence of drug in the standard. No difference wasobserved for standards prepared in buffer compared to standards preparedin serum. Varying the time of incubation of the standards with theantibody/enzyme reagent from 0.25 to 60 minutes before adding thelabeled conjugate did not alter the standard curve. Hence, the assay canbe performed as rapidly as the reagents can be mixed.

D. Assay Procedure--Fixed-Time Assay

A reagent was prepared by adding 140 μl of antiserum to gentamicin(prepared as in part B above--to inhibt the maximum reaction rate in thefinal reagent by 75%) to 40 milliliter (ml) of 0.05 M Bicine buffer, pH8.2. To 2.0 μl aliquots of this reagent in a cuvette were added 7.5 μlaliquots of serum standards. After mixing, 40 μl of an aqueous solutionof the labeled conjugate prepared in part A (0.013 A₃₄₅ units per ml)were added to each cuvette. After further mixing, 30 μl ofβ-galactosidase solution (21 U/μl) were added to each cuvette and thesolutions again mixed. After 20 minutes at room temperature, theresulting fluorescence for each cuvette was measured in the fluorometerand expressed in terms of the instrument reading.

E. Results--Fixed-Time Assay

A standard curve generated by testing various standard samplescontaining known concentrations of gentamicin according to the precedingmethod is depicted in FIG. 4 of the drawings.

EXAMPLE 2 Sisomicin Assay A. Preparation of glycone-dye-drug conjugate

The labeled conjugate used in this Example was that prepared accordingto part A of Example 1.

B. Assay Procedure

A reagent was prepared by adding 170 μl of antiserum to gentamicin(prepared as in part B of Example 1--to inhibit the maximum reactionrate in the final reagent by 90%) and 150 μl of 0.1 mg/mlβ-galactosidase (6U) to 200 ml of 50 mM Bicine buffer. To 2.0 mlaliquots of this reagent in a cuvette were added 20 μl aliquots ofaqueous standard sisomicin solutions. After mixing, 20 μl of an aqueoussolution of the labeled conjugate (part A above--0.032 A₃₄₅ units perml) were added to each cuvette. Fluorescence was measured in anAminco-Bowman Spectrofluorometer and reaction rates calculated for eachstandard as in part C of Example 1.

C. Results

A standard curve generated by testing various standard samples ofsisomicin according to the preceding method is depicted in FIG. 5 of thedrawings.

EXAMPLE 3 Netilmicin Assay A. Preparation of glycone-dye-drug conjugate

The labeled conjugate used in this Example was that prepared accordingto part A of Example 1.

B. Assay Procedure

The procedure was the same as that described in part B of Example 2using aqueous netilmicin standards.

C. Results

A standard curve generated for the assay of netilmicin according to theabove procedure is depicted in FIG. 6 of the drawings.

EXAMPLE 4 Tobramycin Assay A. Preparation of glycone-dye-drug conjugate

The reaction sequence and methodology for the preparation of the labeledtobramycin conjugate were basically those of Table 3 and part A ofExample 1, respectively.

With 55 mg (135 μmol) of the potassium salt of7-β-galactosylcoumarin-3-carboxylic acid was mixed 150 mg (220 μmol) oftobramycin (Eli Lilly & Co., Indianapolis, Indiana U.S.A.) in 1.5 ml ofdistilled water. The pH was adjusted to 3.65 by the dropwise addition of1 N hydrochloric acid and the resulting solution cooled in an ice bath.To initiate the coupling reaction, 30 mg (160 μmol) of1-ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride were added.After overnight incubation of 4° C., two drops of 1 N sodium hydroxidewere added to give a pH of 6.1.

The product was purified by chromatography on carboxymethyl Sephadex gel(Pharmacia Laboratories, Inc.) with ammonium formate as eluant. After aninitial wash with 0.05 M ammonium formate to remove unreactedgalactoside, 1.5 M ammonium formate was used to elute conjugatedproducts. Five peaks of material absorbing at 345 nm were eluted, withthe third peak being selected for use in this study.

B. Assay Procedure

A reagent was prepared by adding 150 μl of antiserum to tobramycin(prepared as described in part B of Example 1 using tobramycin in placeof gentamicin in synthesis of the immunogen--to inhibit the maximumreaction rate in the final reagent by 80%) and 250 μl of an aqueoussolution of β-galactosidase (4U/ml) to 100 ml of 0.05 M Bicine buffer,pH 8.2. To 2.0 ml aliquots of this reagent in a cuvette were added 10 μlaliquots of aqueous standard tobramycin solutions followed by 20 μl ofan aqueous solution of the labeled conjugate prepared as in part A (0.03A₃₄₅ units per ml). After measuring the rate of resulting fluorescence,reaction rates were calculated for each standard as in part C of Example1.

C. Results

A standard curve generated by testing various tobramycin standardsamples according to the preceding method is depicted in FIG. 7 of thedrawings.

EXAMPLE 5 Kanamycin Assay A. Preparation of glycone-dye-drug conjugate

The labeled conjugate used in this Example was that prepared accordingto part A of Example 4.

B. Assay Procedure

The procedure was the same as that described in part B of Example 4using aqueous kanamycin standards.

C. Results

A standard curve generated for the assay of kanamycin according to theabove procedure is depicted in FIG. 8 of the drawings.

EXAMPLE 6 Amikacin Assay A. Preparation of glycone-dye-drug conjugate

The reaction sequence and methodology for the preparation of the labeledamikacin conjugate were basically those of Table 3 and part A of Example1, respectively.

290 mg (540 μmol) of amikacin (Bristol Laboratories, Syracuse, N.Y.U.S.A.) were mixed 110 mg (270 μmol) of the potassium salt of7-β-galactosylcoumarin-3-carboxylic acid in 3 ml of distilled water. ThepH was adjusted to 4.1 by addition of 1 N hydrochloric acid. After thesolution had been cooled in an ice bath, 55 mg (292 μmol) of1-ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride were addedto initiate the reaction. After overnight incubation at 4° C., thereaction mixture was chromatographed on carboxymethyl Sephadex gel.After washing the column with 0.05 M ammonium formate to removeunreacted galactoside, 1.5 M ammonium formate was used to elute thedesired conjugate. Three peaks of material absorbing at 345 nm wereobtained, with the last peak being used for this study.

B. Assay Procedure

A reagent was prepared by adding 80 μl of antiserum to amikacin(prepared as described in part B of Example 1 using amikacin in place ofgentamicin in synthesis of the immunogen--to inhibit the maximumreaction rate in the final reagent by 70%) and 60 μl of an aqueoussolution of β-galactosidase (4 U/ml) to 60 ml of 0.05 M Bicine buffer,pH 8.2. To 2.0 ml aliquots of this reagent in a cuvette were added 10 μlaliquots of aqueous amikacin standard solutions followed by 20 μl of anaqueous solution of the labeled conjugate prepared as in part A (0.03A₃₄₅ units per ml). After measuring the rate of resulting fluorescence,reaction rates were calculated for each standard as in part C of Example1.

C. Results

A standard curve generated by testing various amikacin standard samplesaccording to the preceding method is depicted in FIG. 9 of the drawings.

EXAMPLE 7 Diphenylhydantoin Assay

Diphenylhydantoin [5,5-diphenyl-2,4-imidazolidinedione, cf. The MerckIndex, 9th ed., p. 952(1976)], also known by the generic name phenytoinand sold under various trademarks including Dilantin, is ananti-convulsant drug useful in the management of epilepsy. In mostpatients, the therapeutic range of serum concentration lies between 10and 20 μg/ml whereas toxic signs of nystagmus, ataxia, and mentalchanges almost invariably occur at blood levels over 20 μg/ml.

A. Preparation of glycone-dye-drug conjugate

In a liter, 3-neck round bottom flask was placed 8.64 g of a 50%suspension of sodium hydride (NaH) in mineral oil (0.18 mol). The NaHwas washed free of mineral oil with hexane under an argon atmosphere. Itwas then suspended in 350 ml of dry dimethylformamide (DMF) and stirredwhile a solution of 34.4 g (0.173 mol) of N-(4-bromobutyl)phthalimide in150 ml of dry DMF was added over a 20 minute period. After stirring atroom temperature for 18 hours, the reaction was diluted with 200 ml ofwater and the precipitate collected and dried to yield 49 g of2-[(4-N-phthalimido)butoxy]benzophenone, mp 119°-121° C. A 1 g samplewas recrystallized from ethanol to give 740 mg of white needles, mp121°-122° C.

A mixture of 22.4 g (0.056 mol) of2-[(4-N-phthalimido)butoxy]benzophenone, 4.15 g (0.064 mol) of potassiumcyanide, 17.3 g (0.18 mol) of ammonium carbonate, 24 ml of water, and200 ml of DMF was placed in a steel autoclave and heated at 110° C. for4 days. The contents were cooled and adsorbed onto 100 g of silica gel60 and placed atop a column of 700 g of silica gel made up in 9:1 (v:v)carbon tetrachloride:acetone. Elution was with the same solvent andfractions of approximately 20 ml volumes were collected. Fractions276-803 were combined and evaporated to give 4.65 g of solid.Recrystallization from ethanol gave 2.65 of5-[2-(4-N-formylamino)butoxyphenyl]-5-phenylhydantoin as a white solid,mp 201°-203° C.

A solution of 3.5 g (9.4 mmol) of5-[2-(4-N-formylamino)butoxyphenyl]-5-phenylhydantoin in 100 ml of 1 Nsodium hydroxide was heated on the steam bath for 24 hours. The solutionwas cooled and neutralized with carbon dioxide until precipitationceased. The precipitate was filtered and recrystallized twice; firstfrom pyridine-2-propanol, then from methanol to give 1.5 g of5-[2-(4-aminobutoxy)phenyl]-4-phenylhydantoin as fine white crystals, mp235° C. (decomp).

A mixture of 808 mg (2 mmol) of the potassium salt of7-β-galactosylcoumarin-3-carboxylic acid [Burd et al, Clin. Chem.23:1402(1977)] and 20 ml of dry DMF was made and cooled to 0° C. To thismixture was added 216 mg (2 mmol) of ethylchloroformate. After stirringfor one hour at this temperature, 638 mg (2 mmol) of5-[2-(4-aminobutoxy)phenyl]-5-phenylhydantoin, 244 mg of4-dimethylaminopyridine, and 5 ml of dry pyridine were added. Afterstirring for 5 hours, the reaction was stored overnight at 0° C., thenadsorbed onto 7 g of silica gel 60. The impregnated silica gel wasplaced atop a column of 200 g of silica gel 60 and the column elutedwith a gradient of 2 liters of ethyl acetate to 2 liters of 1:1 (v:v)ethyl acetate:ethanol. Ten ml fractions were collected. Fractions143-160 were combined to give approximately 200 mg of the labeledconjugateN-{4-[2-(5-phenylhydantoinyl-5)phenoxy]butyl}-7-β-galactosylcoumarin-3-carboxamideas a glassy solid.

The solid was taken up in methanol and chromatographed on Sephadex LH-20(45 cm by 3.2 cm), eluting with methanol. Seven ml fractions werecollected. Fractions 30 to 40 were combined and evaporated to give 100mg of the desired labeled conjugate as a pale, glossy solid.

Analysis: Calculated for C₃₅ H₃₅ N₃ O₁₂.H₂ O: C, 59.40; H, 5.24; N,4.95. Found: C, 59.51; H, 5.04; N, 6.14.

[α]_(D) =-39.04° (c 1.0, methanol).

B. Assay Procedure

A reagent was prepared containing β-galactosidase (0.018 U/ml) andantiserum to diphenylhydantoin (raised againsto-caproyldiphenylhydantoin-in an amount sufficient in the final reagentto decrease fluorescence to 10% of that observed in the absence ofantibody) in 50 mmolar Bicine buffer, pH 8.2. To 3.0 ml aliquots of thisreagent in a cuvette were added 100 μl aliquots of the labeled conjugate(part A above). After mixing, the reaction mixtures were incubated 20minutes at room temperature and fluorescence measured in each cuvette(excitation and emission wavelengths were 400 and 450 nm, respectively).

C. Results

A standard curve generated for the assay of diphenylhydantoin accordingto the above procedure is depicted in FIG. 10 of the drawings.

EXAMPLE 8 Fixed-Time Assays for the Aminoglycoside Antibiotics A.Reagents

1. Buffer--Bicine buffer [N,N-bis-(2-hydroxyethyl)-glycine fromCalbiochem, La Jolla, CA] was used at 50 mM, pH 8.5, at 25° C.

2. Enzyme--E. coli grade IV β-galactosidase was used (WorthingtonBiochemicals, Co., Freehold, N.J.). One unit of enzyme hydrolyzes 1.0μmol of o-nitrophenyl-β-D-galactoside per minute when assayed at 25° C.in 50 mM Bicine buffer with 0.1% NaN₃, pH 8.5, containing 3 mMo-nitrophenyl-β-D-galactoside.

3. Antiserum, Standards and Fluorogenic Reagent-These are listed in theReagent Table below as used for the fixed-time assay of the indicatedaminoglycoside antibiotics. The Fluorogenic Reagents consisted of asolution prepared in 5 mM formate-0.1% sodium azide buffer, pH 3.5,which contained 0.007 A₃₄₃ units of the respective labeled conjugate.

B. Fixed-Time Assay Procedure

A reagent was prepared in 50 mM Bicine buffer, pH 8.5, which contained0.05 units of β-galactosidase per ml and an amount of antiserumsufficient to decrease the enzyme reaction to about 30% of that observedin the absence of an antiserum. To 3.0 ml of this reagent in individualcuvettes was added 100 μl of a standard which had been previouslydiluted 1 part to 50 parts of buffer. At 30 second intervals, 100 μl ofthe Fluorogenic Reagent was added to the cuvettes and the contents mixedby gentle inversion of the cuvettes. At 20 minutes after addition of theFluorogenic Reagent, the fluorescence intensity in the individualcuvettes was measured with an Aminco-Bowman Spectrophotofluorometer(American Instrument Co., Silver Springs, Maryland) using 400 nm forexcitation and 450 nm for emission. All fluorescence measurements wereconducted at 25° C.

    ______________________________________                                        REAGENT TABLE                                                                          Immunogen                                                                     used to                                                              Ligand Under                                                                           raise     Ligand used to                                                                             Fluorogenic                                   Assay    Antiserum.sup.1                                                                         prepare Standards                                                                          Reagent                                       ______________________________________                                        Gentamicin                                                                             Gentamicin                                                                              USP Gentamicin                                                                             βGU.sup.2 -sisomicin                                                     (Ex. 1, Part A)                               Sisomicin                                                                              Gentamicin                                                                              Sisomicin sulfate.sup.3                                                                    βGU.sup.2 -sisomicin                                                     (Ex. 1, Part A)                               Netilmicin                                                                             Gentamicin                                                                              Netilmicin   βGU.sup.2 -sisomicin                                        Standards.sup. 4                                                                           (Ex. 1, Part A)                               Tobramycin                                                                             Kanamycin USP Tobramycin                                                                             βGU-tobramycin                                                           (Ex. 4, Part A)                               Kanamycin                                                                              Kanamycin Kanamycin    βGU-tobramycin                                              sulfate.sup.5                                                                              (Ex. 4, Part A)                               Amikacin Amikacin  Amikacin.sup.5                                                                             βGU-amikacin                                                             (Ex. 6, Part A)                               ______________________________________                                         .sup.1 raised in rabbits against BSAantibiotic conjugate                      .sup.2 galactosyl-umbelliferone                                               .sup.3 from Schering Corp., Bloomfield, New Jersey                            .sup.4 purchased from Monitor Science Corp. Newport Beach, California         .sup.5 from Bristol Laboratories, Syracuse, New York                     

C. Results

For each respective aminoglycoside antibiotic assay, the cuvettecontaining the highest standard was used to set the fluorescence meterto a predetermined reading as indicated in the Results Table below.Further readings were then made without adjusting the fluorometer. Theresults are given in the Results Table below.

    ______________________________________                                        RESULTS TABLE                                                                                           Fluorescence                                                    Concentration of                                                                            Intensity                                           Ligand Under Assay                                                                        Standard (μg/ml)                                                                         (Arbitrary Units)                                   ______________________________________                                        Gentamicin  12            93.5                                                            8             78.5                                                            4             54.5                                                            1             34.5                                                Sisomicin   20            90.0                                                            14            77.3                                                            10            71.0                                                            6             47.3                                                            2             24.0                                                            0             19.3                                                Netilmicin  16            74.8                                                            8             62.8                                                            4             47.0                                                            2             36.5                                                            1             33.2                                                Tobramycin  12            81.7                                                            8             66.3                                                            4             48.7                                                            1             37.3                                                Kanamycin   40            87.7                                                            25            71.5                                                            10            47.8                                                            5             39.5                                                            0             32.0                                                Amikacin    40            90.0                                                            30            81.5                                                            20            66.0                                                            10            47.5                                                            0             33.5                                                ______________________________________                                    

EXAMPLE 9 Phenobarbital Assay

Phenobarbital [5-ethyl-5-phenylbarbituric acid, cf. The Merck Index, 9thed., p. 939(1976)], sold under various trademarks including Luminal, isan anticonvulsant drug useful in the management of epilepsy. In mostpatients, the therapeutic range of serum concentration lies between 15and 40 μg/ml whereas toxicity almost invariably appears at blood levelsover 50 μg/ml.

A. Preparation of glycone-dye-drug conjugate

β-galactosyl-umbelliferone labeled phenobarbital conjugates are preparedaccording to the reaction scheme shown in Table B in the drawings. Thissynthetic route is exemplified by the following method of preparing5-[4-(7-β-galactosylcoumarin-3-carboxamido)butyl]-5-phenylbarbituricacid (6), n=4.

Diethyl 2-Carbethoxy-2-phenylpimelate (1)

A 50% mineral oil dispersion of 2.4 g (0.1 mol) of sodium hydride wasplaced in a 500 ml, 3-neck round bottom flask under an argon atmosphere.It was washed free of oil with 250 ml of dry hexane and combined with23.6 g (0.1 mol) of diethyl phenylmalonate (Aldrich Chemical Co.,Milwaukee, WI) dissolved in 100 ml of dry dimethylformamide (DMF). Themixture was stirred at room temperature for 15 minutes, during whichtime hydrogen evolution ceased. A solution of 20.9 g (0.1 mol) of ethyl5-bromopentanoate (Aldrich Chemical Co., Milwaukee, WI) in 100 ml of dryDMF was added and the reaction stirred overnight at 70° C. Removal ofthe DMF on a rotary evaporator at 50° C./0.3 mm left an oily residuethat was partitioned between 300 ml of water and 500 ml of ethylacetate. The organic phase was separated, washed with 500 ml of water,200 ml of saturated sodium chloride solution, and dried over anhydrousmagnesium sulfate. It was filtered and evaporated to give an oil thatwas chromatographed on 1500 g of silica gel (E. Merck Co., Darmstadt,West Germany). The column was eluted with chloroform and 20 ml fractionswere collected.

Fractions 771 to 1200 were combined and evaporated to give an oil thatwas evaporatively distilled at 160° C./0.01 mm to yield 28 g (77% yield)of the desired product (1) as a white oil.

Analysis: Calculated for C₂₀ H₂₈ O₆ : C, 65.91; H, 7.74. Found: C,65.90; H, 7.75.

Infrared Spectrum (neat): 1735 cm⁻¹ (carbonyl).

5-(4-Carbethoxybutyl)-5-phenyl-2-thiobarbituric Acid (2) and5-(4-Carboxybutyl)-5-phenylbarbituric Acid (3).

A solution of 3.68 g (0.16 g-atm) of sodium and 15.2 g (0.2 mol) ofthiourea in 100 ml of ethanol was refluxed while stirring under an argonatmosphere. To this was added, dropwise over 30 minutes, 28 g (0.08 mol)of diethyl 2-carbethoxy-2-phenylpimelate (1). After refluxing for 6hours, the reaction was cooled and concentrated on a rotary evaporator.The residue was taken up in 200 ml of water and extracted with 200 ml ofethyl acetate followed by 200 ml of ether. The aqueous phase wasacidified to pH 1 which caused the precipitation of a heavy yellow oil.This oil was chromatographed on 850 g of silica gel. The column waseluted with 9:1 (v:v) toluene:ethanol and 20 ml fractions werecollected.

Fractions 45 to 63 were combined, evaporated to dryness, and the solidresidue recrystallized from aqueous ethanol. This gave 5 g (18% yield)of the thiobarbituric acid (2) as pale yellow crystals, mp 121° C.

Analysis: Calculated for C₁₇ H₂₆ N₂ SO₄ : C, 58.60; H, 5.79; N, 8.04.Found: C, 58.42; H, 5.82; N, 8.07.

Infrared Spectrum (KCl): 1735 cm⁻¹ (carbonyl); 1675 cm⁻¹ (carbonyl).

Fractions 64 to 100 were combined and evaporated to give 6 g of slightlyimpure (2). This was taken up in 50 ml of dimethyl sulfoxide containing1 ml of concentrated sulfuric acid and heated on the steam bath for 3hours. [Mikolajczyk and Luczak, Chem. Ind. 77 (1972)]. When cool, thedimethyl sulfoxide was removed under high vacuum. To the residue wasadded 25 ml water and 25 ml of dioxane and the solution heated on thesteam bath for 2 hours. Removal of the solvent gave a dark residue thatwas partitioned between 200 ml of ether and 200 ml of aqueous sodiumbicarbonate solution. The aqueous phase was filtered and neutralizedwith hydrochloric acid. A solid precipitated that was recrystallizedfrom aqueous ethanol to give 1.9 g (36% yield) of the barbituric acid(3) as white crystals, mp 202°-203° C.

Analysis: Calculated for C₁₅ H₁₆ N₂ O₅ : C, 59.20; H, 5.30; N, 9.21.Found: C, 58.65; H, 5.34; N, 9.25.

NMR Spectrum (C₅ D₅ N): δ 1.9 (m, 4H); δ 2.6 (m, 4H); δ 7.3 (m, 3H); δ7.8 (m, 2H).

5-(4-Aminobutyl)-5-phenylbarbituric Acid (4)

A mixture of 15 ml of concentrated sulfuric acid, 7 g (0.023 mol) ofbarbituric acid (3) and 3.45 g (0.053 mol) of sodium azide was placed ina small, stainless steel stirring autoclave and heated to 60° C. After90 minutes the autoclave was cooled, opened, and the black suspensionrinsed out with 300 ml of water and neutralized with solid sodiumbicarbonate. It was combined with 50 g of celite (Fischer ScientificCo., Pittsburgh, PA) and the water removed on a rotary evaporator. Thisleft a dirty gray mass that was air dried, then ground to a fineconsistency in a mortar. It was placed atop a 250 g column of silica gelmade up in 9:1 (v:v) ethanol:1 M aqueous triethylammonium bicarbonate.The column was eluted with this solvent and 20 ml fractions werecollected.

Fractions 73 to 107 were combined and evaporated to give a solidresidue. It was taken up in dilute hydrochloric acid, evaporated todryness, and this residue recrystallized from ethanol to give 1.75 g(24% yield) of the hydrochloride salt of5-(4-aminobutyl)-5-phenylbarbituric acid (4) as fine white needles thatdid not melt below 280° C.

Analysis: Calculated for C₁₄ H₁₇ N₃ O₃.HCl: C, 53.93; H, 5.82; N, 13.48.Found: C, 53.44; H, 5.94; N, 13.29.

Infrared Spectrum (KCl): 1710 cm⁻¹ (carbonyl).

5-[4-(7-β-Galactosylcoumarin-3-carboxamido)butyl]-5-phenylbarbituricAcid (6).

A mixture of 737 mg (2 mmol) of 7-β-galactosylcoumarin-3-carboxylic acid[Burd et al, Clin. Chem. 23:1402(1977)], 0.278 ml (202 mg, 2 mmol) oftriethylamine, and 25 ml of dimethylformamide was cooled to -5° C. in amethanol-ice bath while stirring under an aargon atmosphere. To this wasadded 273 mg (2 mmol) of isobutyl chloroformate. After 1 hour at thistemperature a precipitate of triethylamine was present, indicatingconversion to the mixed anhydride (5). At this point, 551 mg (2 mmol) ofthe amine (4) was added. The reaction was stirred at -5° C. for 2 hours,then allowed to warm to room temperature overnight. Eight grams ofsilica gel was added and the solvent removed on a rotary evaporatorunder high vacuum. The impregnated silica gel was placed atop a columnof 200 g of silica gel made up in ethyl acetate. The column was elutedwith a gradient of 2 L of ethyl acetate to 2 L of 1:1 (v:v) ethylacetate:ethanol and 15 ml fractions were collected.

Fractions 126 to 175 were combined and evaporated to give 750 mg (80%yield) of the desired conjugate (6) as a white solid, mp 161°-163° C.

Analysis: Calculated for C₃₀ H₃₁ N₃ O₁₂ : C, 57.60; H, 4.99; N, 6.72.Found: C, 57,54; H, 5.29; N, 6.27.

Infrared Spectrum (KCl): 1710 cm⁻¹ (carbonyl).

Optical Rotation: [α]_(D) =-45.48° (c 1.0, CH₃ OH).

Mass Spectrum (field desorption): m/e 626 [O+1].

The above-described synthesis of the β-galactosylcoumarinphenobarbitalconjugate (6) (n=4) can be modified to yield labeled conjugates whereinn=2 through 6 by replacing the starting material ethyl 5-bromopentanoatewith the appropriate ethyl ω-bromoalkanoate as follows:

    ______________________________________                                        n                 alkylene                                                    ______________________________________                                        2                 ethylene                                                    3                 propylene                                                   5                 pentylene                                                   6                 hexylene                                                    ______________________________________                                    

B. Assay Reagents

1. Antiserum--Antiserum was collected from rabbits which were immunizedwith a phenobarbital-bovine serum albumin immunogen conjugate.

2. Enzyme--E. coli grade IV β-galactosidase was used (WorthingtonBiochemicals, Co., Freehold, NJ). One unit of enzyme hydrolyzes 1.0μmole of o-nitrophenyl-β-D-galactoside per minute when assayed at 25° C.in 50 mM Bicine buffer [N,N-bis-(2-hydroxyethyl)-glycine fromCalbiochem, La Jolla, CA], pH 8.5, containing 3 mMo-nitrophenyl-β-D-galactoside.

3. Buffer--Bicine buffer was used at 50 mmolar, pH 8.5, at 25° C.

4. Phenobarbital standards were prepared from USP primary standardmaterials.

5. Fluorogenic Phenobarbital Reagent--A solution was prepared in 5 mMformate--0.1% azide buffer, pH 3.5, which contained 0.016 absorbanceunits at 343 nm (A₃₄₃) of β-galactosyl-umbelliferonephenobarbital (PartA).

C. Assay Procedure

A reagent was prepared in 50 mM Bicine buffer, pH 8.5, which contained0.05 units of β-galactosidase per ml and an amount of antiserumsufficient to decrease the enzyme reaction to about 15% of that observedin the absence of antiserum. To 3.0 ml of this reagent in individualcuvettes was added 100 μl of phenobarbital standards which hadpreviously been diluted 1 part to 50 parts of buffer. At 30 secondintervals, 100 μl of the Fluorogenic Phenobarbital Reagent were added tothe cuvettes and the contents mixed by gentle inversion of the cuvettes.At 20 minutes after addition of the Fluorogenic Phenobarbital Reagent,the fluoresence intensity in the individual cuvettes was measured withan Aminco-Bowman Spectrophotofluorometer (American Instrument Co.,Silver Springs, Maryland). Excitation and emission wavelengths were setat 400 and 450 nm, respectively. All fluorescence measurements wereconducted at 25° C.

D. Results

The cuvette containing the highest phenobarbital standard was used toset the fluorescence meter to a reading of 90 units. Further readingswere then made without adjusting the fluorometer. A standard curvegenerated for the assay of phenobarbital according to the aboveprocedure is depicted in FIG. 11 of the drawings.

EXAMPLE 10 Theophylline Assay

Theophylline [1,3-dimethylxanthine, of The Merck Index, 9th ed., p.1196(1976)] is a drug useful in the management of asthma. In mostpatients, the therapeutic range of serum concentration lies between 10and 20 μg/ml whereas toxicity almost invariably appears at blood levelsover 35 μg/ml.

A. Preparation of glycone-dye-drug conjugate

β-galactosyl-umbelliferone-labelled theophylline conjugates are preparedaccording to the reaction scheme shown in Table C in the drawings. Thissynthetic route is exemplified by the following method of preparing8-[3-(7-β-galactosylcoumarin-3-carboxamido)propyl]theophylline (10),n=3.

8-(3-Aminopropyl)theophylline (8)

A mixture of 2.66 g (0.01 mol) of 8-(3-carboxypropyl)theophylline (7)[Cook et al, Res. Commun. Chem. Path. Pharmacol. 13(3):497-505(1976)],20 ml of chloroform, and 3 ml of concentrated sulfuric acid was stirredat 50° C. under an argon atmosphere. To this was added 1.3 g of solidsodium azide portionwise over a 90 minute period [cf. Organic Reactions47:28(1967)]. The reaction was cooled and the solvent removed underreduced pressure. The residue was combined with enough sodiumbicarbonate solution to bring the pH to 7.5. Ten grams of celite (FisherScientific Co., Pittsburgh, PA) was added and the water evaporated. Theimpregnated celite was placed atop a column of 200 g of silica gel (E.Merck Co., Darmstadt, West Germany) made up in 9:1 (v:v) ethanol--1molar aqueous triethylammonium bicarbonate. The column was eluted withthis solvent and 15 ml fractions were collected. Fractions 171 to 225were combined and evaporated to give 500 mg of a white powder. Thissubstance was rechromatographed on a column of CM-Sephadex, ammoniumform (Pharmacia Fine Chemicals, Piscataway, NJ), eluting with 0.5 molarammonium bicarbonate. The bed volume was 3 cm by 50 cm; and 10 mlfractions were collected. Fractions 65 to 110 were combined andevaporated to give 250 mg of a white solid. It was taken up in dilutehydrochloric acid, then reevaporated.

The residue was recrystallized from methanol to give 90 mg (3% yield) ofthe hydrochloric acid salt of (8) as pale tan needles that did not meltbelow 300° C.

Analysis: Calculated for C₁₀ H₁₆ N₅ ClO₂ : C, 43.88; H, 5.89; N, 25.59.Found: C, 43.77; H, 5.88; N, 25.46.

Infrared Spectrum (KCl): 1695 cm⁻¹ and 1655 cm⁻¹ (amide carbonyls).

8-[3-(7-β-Galactosylcoumarin-3-carboxamido)propyl]theophylline (10)

A reaction mixture was prepared containing 24 g of potassium hydroxide,80 ml of water, 240 ml of ethanol and 20 g (0.035 mmol) of ethyl7-β-galactosylcoumarin-3-carboxylate [Burd et al, Clin. Chem. 23:1402(1977)]. The reaction was stirred at 50° C. for 15 hours. When cool, themethanol was removed under reduced pressure. The concentrated aqueoussolution was acidified to pH 2.0 with concentrated hydrochloric acid.The white precipitate was collected, washed with cold water, andrecrystallized from hot water. The crystals were collected, washed withacetone, and dried at 80° C. for 1 hour. This gave 12 g of7-β-galactosylcoumarin-3-carboxylic acid as white crystals, mp 250°-255°C.

A mixture of 1.45 g (0.004 mol) of 7-β-galactosylcoumarin-3-carboxylicacid, 404 mg (0.004 mol) of triethylamine, and 40 ml of dry dimethylformamide (DMF) was cooled to -10° C. while stirring under argon. Tothis was added 546 mg (0.004 mol) of isobutyl chloroformate (AldrichChemical Co., Milwaukee, WI) to form the mixed anhydride (9). Tenminutes later, an additional 404 mg of triethylamine and 949 mg (0.004mol) of 8-(3-aminopropyl)theophylline (8) was added to the flask. Afterstirring for 30 minutes at -10° C., the reaction was allowed to warm toroom temperature. It was combined with 10 g of silica gel and the DMFremoved under high vacuum. The impregnated silica gel was placed atop acolumn of 170 g of silica gel and the column eluted with anhydrousethanol and collecting 15 ml fractions. Fractions 41 to 475 werecombined and evaporated to give 545 mg of a yellow solid. It wasdissolved in water, filtered, and concentrated to a 20 ml volume. Asmall amount of precipitate formed and was discarded. The filtrate waschromatographed on a 2.5 cm by 57 cm column of Sephadex LH-20 gel(Pharmacia Fine Chemicals, Piscataway, NJ), eluting with water andcollecting 15 ml fractions. Fractions 18 to 23 were combined,evaporated, and the residue recrystallized from water to give 55 mg (2%yield) of the labeled conjugate (10) as a light yellow solid, mp190°-192° C.

Analysis: Calculated for C₂₆ H₂₉ N₅ O₁₁ : C, 53.15; H, 4.98; N, 11.92.Found: C, 52.65; H, 5.01; N, 11.80.

The above-described synthesis of the β-galactosylcoumarin-theophyllineconjugate (10), n=3, can be modified to yield labeled conjugates whereinn=2 through 6 by replacing the starting material8-(3-carboxypropyl)theophylline (7), n=3, with the appropriate8-(ω-carboxyalkyl)theophylline as follows:

    ______________________________________                                        n                 alkylene                                                    ______________________________________                                        2                 ethylene                                                    4                 butylene                                                    5                 pentylene                                                   6                 hexylene                                                    ______________________________________                                    

B. Assay Reagents

1. Antiserum--Antiserum was collected from rabbits immunized with atheophylline immunogen conjugate prepared as described by Cook et al,Res. Comm. Chem. Path. Pharmacol. 13:497-505(1976).

2. Enzyme and Buffer--Same as those described in Parts B-2 and B-3 inExample 9.

3. Theophylline standards were prepared from USP theophylline referencestandard and normal human serum containing from 0 to 40 μg/ml oftheophylline.

4. Fluorogenic Theophylline Reagent--A solution was prepared in 5 mMformate--0.1% sodium azide buffer, pH 3.5, which contained 0.01 A₃₄₈units (12.3 mM) of the labeled conjugate (Part A).

C. Assay Procedure and Results

The procedure was the same as in Example 9 using theophylline standardsand Fluorogenic Theophylline Reagent in place of the phenobarbitalreagents. A standard curve generated for the assay of theophyllineaccording to this procedure is depicted in FIG. 12 of the drawings.

EXAMPLE 11 Carbamazepine Assay

Carbamazepine [5H-dibenz[b,f]azepine-5-carboxamide, cf. The Merck Index,9th ed., p. 226(1976)], sold under various trademarks includingTegretol, is an anti-convulsant drug useful in the management ofepilepsy. The therapeutic range of serum concentration in most patientslies between 4 and 12 μg/ml whereas toxic signs may appear at bloodlevels over 12 μg/ml.

A. Preparation of glycone-dye-drug conjugate

β-galactosyl-umbelliferone-labeled carbamazepine conjugates are preparedaccording to the reaction scheme shown in Table D in the drawings. Thissynthetic route is exemplified by the following method of preparingN-[4-(7-β-galactosylcoumarin-3-carboxamido)butyl]aminocarbonyl-5H-dibenz[b,f]azepine(14), n=4.

N-(4-Aminobutyl)aminocarbonyl-5H-dibenz[b,f]azepine (12)

Phosgene gas was bubbled into a room temperature suspension of 14.1 g(0.073 mol) of 5H-dibenz[b,f]-azepine (Aldrich Chemical Co., Milwaukee,WI) in 180 ml of dry toluene until 15 g was absorbed. The warm mixturewas stirred for 2 hours, heated at reflux for 2 hours, then stirred atroom temperature overnight. The yellow solution, now containingN-chlorocarbonyl-5H-dibenz[b,f]azepine (11), was concentrated by boilingto about 100 ml volume. It was added dropwise over 1 hour to a solutionat room temperature of 26 g (0.29 mol) of 1,4-diaminobutane in 250 ml oftoluene. A white crystalline solid began to precipitate immediately.After the addition was complete, the resulting slurry was stirred atreflux for 3 hours. It was then cooled, filtered, and the precipitatewashed with toluene. The filtrate was evaporated and excess butanediamine was removed by heating to 100° C. at 0.2 mm. The residual oilwas taken up in dilute hydrochloric acid and some insoluble materialfiltered off. The solution was made basic to pH 9.5 with sodiumcarbonate and extracted with chloroform. Evaporation of this extractgave a glass that solidified when triturated with ether. This gave 15.8g (70% yield) of the amine (12), as a solid, mp 114°-116° C.

Analysis: Calculated for C₁₉ H₂₁ N₃ O: C, 74.24; H, 6.89; N, 13.67.Found: C, 73.92; H, 6.71; N, 13.64.

Infrared Spectrum (KCl); 1655 cm⁻¹ (amide carbonyl).

N-[4-(7-β-Galactosylcoumarin-3-carboxamido)butyl]aminocarbonyl-5H-dibenz[b,f]azepine(14)

A mixture of 24 g of potassium hydroxide, 80 ml of water, 240 ml ofmethanol, and 20 g (0.035 mol) of ethyl7-β-galactosylcoumarin-3-carboxylate [Burd et al, Clin. Chem23:1402(1977)] was stirred at 50° C. for 15 hours. When cool, themethanol was removed under reduced pressure. The concentrated aqueoussolution was acidified to pH 2.0 with concentrated hydrochloric acid.The white precipitate was collected, washed with cold water, andrecrystallized from hot water. The crystals were collected, washed withacetone, and dried at 80° C. for 1 hour. This gave 12 g (54% yield) of7-β-galactosylcoumarin-3-carboxylic acid as white crystals, mp 250°-255°C.

A mixture of 1.02 g (5 mmol) of dicyclohexylcarbodiimide, 575 mg (5mmol) of N-hydroxysuccinimide, and 50 ml of dry dimethylformamide (DMF)was stirred at room temperature under argon for 30 minutes. The clear,colorless solution was cooled to -5° and 1.835 g (5 mmol) of7-β-galactosylcoumarin-3-carboxylic acid was added. The reaction wasallowed to warm to room temperature and stirred for 2 hours. The mixturewas then cooled in an ice bath and the precipitate of dicyclohexyl urearemoved by filtration under argon. The filtrate, now containing theN-hydroxysuccinimide ester (13), was combined with 1.54 g (5 mmol) ofN-(4-aminobutyl)aminocarbonyl-5H-dibenz[b,f]azepine (12) dissolved in 5ml of DMF. The reaction was stirred overnight at room temperature. Thesolvent was removed at 50° C./12 mm on the rotary evaporator and theresidue triturated with dilute aqueous sodium bicarbonate solution. Theinsoluble material was chromatographed on 100 g of silica gel (E. MerckCo., Darmstadt, West Germany) eluting with a gradient of 2 L of ethylacetate to 2 L of ethanol and 20 ml fractions were collected. Fractions190 to 250 were combined, evaporated, and the residue recrystallizedtwice from ethanol. This gave 1.0 g (30% yield) of the labeled conjugate(14) as a white powder, mp 150°-160° C. (decomposed).

Analysis: Calculated for C₃₅ H₃₅ N₃ O₁₀ : C, 63.95; H, 5.35; N, 6.39.Found: C, 63.55; H, 5.77; N, 6.14.

Mass Spectrum (field desorption): m/e 658, [P+1].

Optical Rotation: [α]_(D) =-46.84° (c 1.0, MeOH)

The above-described synthesis of the β-galactosylcoumarincarbamazepineconjugate (14), n=4, can be modified to yield labeled conjugates whereinn=2 through 6 by replacing the starting material 1,4-diaminobutane withthe appropriate α,ω-diaminoalkane as follows:

    ______________________________________                                        n               α, ω-diaminoalkane                                ______________________________________                                        2               ethylenediamine                                               3               1,3-diaminopropane                                            5               1,5-diaminopentane                                            6               1,6-diaminohexane                                             ______________________________________                                    

B. Assay Reagents

1. Antiserum--Antiserum was obtained by immunization of rabbits with acarbamazepine-bovine serum albumin immunogen conjugate.

2. Enzyme and Buffer--Same as those described in Parts B-2 and B-3 inExample 9.

3. Carbamazepine standards--EMIT® Antiepileptic Drug Calibrators (SyvaCo., Palo Alto, CA) were prepared as described by the manufacturer.

4. Fluorogenic Carbamazepine Reagent--A solution was prepared in 5 mMformate--0.1% azide buffer, pH 3.5, which contained 0.016 A₃₄₃ units ofβ-galactosyl-umbelliferone-carbamazepine (Part A).

C. Assay Procedure and Results

The procedure was the same as in Example 9 using carbamazepine standardsand Fluorogenic Carbamazepine Reagent in place of the phenobarbitalreagents. A standard curve generated for the assay of carbamazepineaccording to this procedure is depicted in FIG. 13 of the drawings.

EXAMPLE 12 Primidone Assay

Primidone [5-ethyl-5-phenylhexahydropyrimidine-4,6-dione, cf. The MerckIndex, 9th ed., p. 1003(1976)], sold under various trademarks includingMysoline, is an anti-convulsant drug useful in the management ofepilepsy. The therapeutic range of serum concentration in almost allpatients lies between 5 and 10 μg/ml whereas toxicity almost invariablyappears at blood levels over 15 μg/ml.

A. Preparation of glycone-dye-drug conjugate

The β-galactosyl-umbelliferone labeled primidone conjugates are preparedaccording to the reaction scheme shown in Table E in the drawings. Thissynthetic route is exemplified by the following method of preparing5-[4-(7-β-galactosylcoumarin-3-carboxamido)butyl]-5-phenyl-2-desoxybarbituricacid (20), n=4.

Diethyl (3-Cyanopropyl)phenylmalonate (15)

A 50% mineral oil dispersion containing 16.8 g (0.7 mol) of sodiumhydride was placed in a 3-liter, three-necked, round-bottom flask andwashed free of oil with 500 ml of dry hexane. To this was added 1.2liters of dry dimethylformamide (DMF) and 165.4 g (0.7 mol) of diethylphenylmalonate (Aldrich Chemical Co., Milwaukee, WI). After hydrogenceased to be evolved (3.5 hours), 104.2 g (0.7 mol) of4-bromobutyronitrile (Aldrich Chemical Co.) was added, and the reactionheated at 65° C. overnight. The solvent was removed under reducedpressure, and the residue suspended in 1 liter of ethyl acetate. It wasfiltered, the filtrate reevaporated, and the residue evaporativelydistilled at 170° C./0.1 mm to give 168 g (79% yield) of the diester(15) as a yellow liquid.

Analysis: Infrared Spectrum (CDCl₃): 2245 cm⁻¹ (CN); 1730 cm⁻¹ (estercarbonyl).

NMR Spectrum (CDCl₃): δ 1.3 (6H, t, J=8 Hz); δ 7.3 (5H, s).

5-(3-Cyanopropyl)-5-phenyl-2-thiobarbituric Acid (16)

A solution of 11.5 g (0.5 g-atm) of sodium and 47.6 g (0.625 mol) ofthiourea in 320 ml of absolute ethanol was stirred at reflux under anargon atmosphere. Over the next 30 minutes, 75.9 g (0.25 mol) of diethyl(3-cyanopropyl)phenylmalonate (15) was added dropwise. Heating wascontinued for 18 hours. When cool, the solvent was removed under reducedpressure, and the residue partitioned between 500 ml of water and 500 mlof ethyl acetate. The aqueous phase was separated, washed with ether,and acidified to pH 1 with concentrated hydrochloric acid. This aqueousmixture was allowed to evaporate to dryness to give a semicrystallinemass. It was digested with 350 ml of boiling chloroform, filtered, andcooled to give 20 g of a light tan solid, mp 130°-145° C.Recrystallization from ethanol gave 8 g (11% yield) of thecyano-thiobarbituric acid (16), as white crystals, mp 199° C.

Analysis: Calculated for C₁₄ H₁₃ N₃ SO₂ : C, 58.52; H, 4.56; N, 14.62.Found: C, 58.59; H, 4.39; N, 14.27.

Mass Spectrum (70 e.v.): m/e 287 [P⁺ ]; m/e 240 [PH⁺ minus CH₂ CH₂ CH₂CN].

5-(3-Cyanopropyl)-5-phenyl-2-desoxybarbituric Acid (17) and5-(4-Aminobutyl)-5-phenyl-2-desoxybarbituric Acid (18)

A mixture of 8 g (0.029 mol) of5-(3-cyanopropyl)-5-phenyl-2-thiobarbituric acid (16), 50 ml of anisopropanol slurry of freshly prepared W-5 raney nickel (R. L.Augustine, Catalytic Hydrogenation, Marcel Dekker, Inc., New York, 1965,page 27) and 300 ml of ethanol was stirred at reflux under a hydrogenatmosphere for 4 hours. It was filtered while hot and the filtratecooled in an ice bath. The catalyst was washed with 200 ml of hotethanol and then combined with the filtrate. When concentrated to a 50ml volume, a yellow precipitate formed that amounted to 4.1 g when dry.This was chromatographed on 200 g of silica gel 60 (E. Merck Co.,Darmstadt, West Germany). The column was eluted with 9:1 (v:v)toluene:methanol and 20 ml fractions were collected. Fractions 70 to 200were combined, evaporated, and the residue twice recrystallized fromethanol to give 1.8 g (24% yield) of the cyano-desoxybarbituric acid(17) as fine white crystals, mp 253°-254° C.

Analysis: Calculated for C₁₄ H₁₅ N₃ O₂ : C, 65.35; H, 5.88; N, 16.33.Found: C, 65.09; H, 5.56; N, 15.71.

NMR Spectrum (d₆ -DMSO): δ 4.0 (m, 2H); δ 7.4 (s, 5H).

The ethanol filtrate from the original crystallization was evaporated togive a glassy solid that was chromatographed on 250 g of silica gelusing a solvent prepared by equilibrating equal volumes of chloroform,methanol, and concentrated ammonium hydroxide. The lower phase of thismixture was used to elute the column, and 15 ml fractions werecollected. Fractions 66 to 100 were combined, evaporated, and thecrystalline residue slurried in 2-propanol, filtered, and dried. Thisgave 180 mg (2% yield) of white crystals of the amino-desoxybarbituricacid (18), mp 242°-244° C.

Analysis: NMR Spectrum (d₄ -CH₃ OH): δ 3.0 (2H, t, J=8 Hz); δ 4.3 (2H,m); δ 7.3 (s, 5H).

Mass Spectrum (70 e.v.): m/e 261 [P⁺ ]; 218 [P⁺ minus CH₂ =CHNH₂ ].

5-[4-(7-β-Galactosylcoumarin-3-carboxamido)butyl]-5-phenyl-2-desoxybarbituricAcid (20)

A mixture of 24 g of potassium hydroxide, 80 ml of water, 240 ml ofmethanol, and 20 g (0.035 mol) of ethyl7-β-galactosylcoumarin-3-carboxylate [Burd et al, Clin. Chem. 23, 1402(1977)] was stirred at 50° C. for 15 hours. When cool, the methanol wasremoved under reduced pressure. The concentrated aqueous solution wasacidified to pH 2 with concentrated hydrochloric acid. The precipitatewas collected, washed with cold water, and recrystallized from hotwater. The crystals were collected, washed with acetone, and dried at80° C. for 1 hr. This gave 12 g (54% yield) of7-β-galactosylcoumarin-3-carboxylic acid as white crystals, mp 250°-255°C.

A mixture of 210 mg (0.57 mmol) of 7-β-galactosylcoumarin-3-carboxylicacid and 5.7 ml of a 0.1 M solution of triethylamine in dry DMF wascooled to -10° C. while stirring under argon. To this was added 78 mg(0.57 mmol) of isobutyl chloroformate. After 15 minutes at -10° C., thereaction was allowed to warm to 0° C. for an additional 15 minutes. Tothis solution, now containing the mixed anhydride (19), was added 150 mg(0.57 mmol) of 5-(4-aminobutyl)-5-phenyl-2-desoxybarbituric acid (18)and another 5.7 ml of 0.1 M triethylamine-DMF solution. The reaction wasstirred at 0° C. for 15 minutes, then allowed to come to roomtemperature overnight.

Two grams of silica gel 60 was added to the reaction mixture and thesolvent evaporated under high vacuum. The impregnated silica gel wasplaced atop a column of 50 g of silica gel made up in ethyl acetate. Thecolumn was eluted with a gradient of 1 liter of ethyl acetate to 1 literof ethanol, and 10 ml fractions were collected. Fractions 120 to 160were combined and evaporated to give a white solid. Recrystallizationfrom methanol gave 180 mg (51% yield) of the labeled conjugate (20) as awhite powder, mp 181°-183° C.

Analysis: Calculated for C₃₀ H₃₃ N₃ O₁₁ : C, 58.91; H, 5.44; N, 6.89.Found: C, 55.86; H, 5.28; N, 6.37.

Mass Spectrum (Field Desorption): m/e 612 [PH⁺ ].

Optical Rotation: [α]_(D) =-48.38° (c 1.0, CH₃ OH).

The above described synthesis of the β-galactosylcoumarin-primidoneconjugate (20), n=4, can be modified to yield labeled conjugates whereinn=2 through 6 by replacing the starting material 4-bromobutyronitrilewith the appropriate ω-bromoalkyl nitrile as follows:

    ______________________________________                                        n               ω-bromoalkyl nitrile                                    ______________________________________                                        2               2-bromoacetonitrile                                           3               3-bromopropionitrile                                          5               5-bromovaleronitrile                                          6               6-bromocapronitrile                                           ______________________________________                                    

B. Assay Reagents

1. Antiserum--Antiserum was obtained by immunization of rabbits with aprimidone-bovine serum albumin immunogen conjugate.

2. Enzyme and Buffer--Same as those described in Parts B-2 and B-3 inExample 9.

3. Primidone standards--Prepared from dried purified powder purchasedfrom USP-NF Reference Standards.

4. Fluorogenic Primidone Reagent--A solution was prepared in 5 mMformate--0.1% azide buffer, pH 3.5, which contained 0.017 A₃₄₃ units ofβ-galactosyl-umbelliferone-primidone (Part A).

C. Assay Procedure and Results

The procedure was the same as in Example 9 using primidone standards andFluorogenic Primidone Reagent in place of the phenobarbital reagents. Astandard curve generated for the assay of primidone according to thisprocedure is depicted in FIG. 14 of the drawings.

EXAMPLE 13 Immunoglobulin Assays A. Preparation ofglycone-dye-immunoglobulin conjugate

The β-galactosyl-umbelliferone labeled IgG conjugates are preparedaccording to the reaction scheme shown in Table F of the drawings.

This synthetic route is exemplified by the following method of preparinglabeled conjugate (22) wherein n=6, m=4 and p is on the average between5 and 8.

N-(6-Aminohexyl)-7-β-galactosylcoumarin-3-carboxamide (21)

1,6-Hexanediamine (1.76 g, 15 mmoles) was dissolved in 20 ml ofdistilled water and the pH was adjusted to 9 with concentratedhydrochloric acid. 7-β-galactosylcoumarin-3-carboxylic acid (1.83 g, 5mmoles) [Burd et al, Clin. Chem. 23:1402(1977)] was dissolved in thehexanediamine solution and the pH was further adjusted to 5±0.5. Thissolution was cooled to 4° C. in an ice bath.1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.16 g, 6.15 mmoles)[Pierce Chemical Co., Rockford, Ill.] was added to the cooled solutionand the pH was maintained at 5±0.5 manually. The reaction was allowed toproceed at 4° C. for two hours and then two more hours at roomtemperature. At the end of four hours, 80 ml water and 0.6 g (3.2mmoles) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were added to thereaction solution and the pH was maintained at 5. The solution wasstirred continuously overnight at room temperature. Then it was dilutedto 6 L with distilled water and applied onto a column (5×40 cm) ofCM-Sepharose CL in the ammonium form [Pharmacia Fine Chemicals,Piscataway, N.J.]. The column was washed successively with 3 L distilledwater, 1 L of 1 mM ammonium bicarbonate and 2 L of 2 mM ammoniumbicarbonate. The chromatogram was developed with a linear gradientgenerated with 4 L of 2 mM and 4 L of 300 mM ammonium bicarbonate and 10ml fractions were collected. The absorbance of the eluate was monitoredat 280 nm and selected fractions were examined by thin layerchromatography on silica gel 60 plates using a 0.5 M triethylammoniumbicarbonate; pH 7.8:ethanol (3:7) solvent. The fractions eluted between70 and 90 mM ammonium bicarbonate showed several fluorescent spots whenviewed under long wavelength UV light and one spot, R_(f) =0.24, gave apositive reaction with ninhydrin. These fractions were pooled andevaporated to dryness. The residue was dissolved in water and evaporatedto dryness several times to remove the residual ammonium bicarbonate.The yield was less than 10%.

β-Galactosyl-umbelliferone labeled IgG (22)

To 8.5 mg (18 μmoles) of the above product in 2 ml of distilled waterwas added 10 mg (40 μmoles) dimethyladipimidate dihydrochloride [PierceChemical Co., Rockford, Ill.] and 40 μl triethylamine. The solution wasstirred at room temperature for ten minutes and then 40 mg (0.26 μmole)human IgG [Miles Laboratories, Inc., Elkhart, Ind.] in 1 ml of 0.1 Msodium pyrophosphate buffer, pH 8.5, was added. The solution was stirredat room temperature for two additional hours, after which the solutionwas applied onto a column (3×50 cm) of Sephadex G-25 coarse,equilibrated with 0.1 M sodium phosphate pH 7.0. Fractions of 7 ml werecollected. They were monitored at 280 and 340 nm and those containingIgG were pooled and dialyzed at 4° C. successively against 6 L of 0.1 Msodium phosphate, pH 7.0; 6 L of 0.1 M sodium phosphate, pH 7.0,containing 1 M sodium chloride; and 6 L of 0.1 M sodium phosphate, pH7.0, for 18 hours each.

The above described synthesis of the β-galactosyl-umbelliferone-IgGconjugate (22), n=6, m=4, can be modified to yield labeled conjugateswherein n=2-8 and m=1-10 by replacing the starting materials1,6-hexanediamine and dimethyl adipimidate, respectively, with theappropriate α,ω-alkyldiamine and dimethyl alkyldiimidate as follows:

    ______________________________________                                        n               β, ω-alkyldiamine                                  ______________________________________                                        2               ethylenediamine                                               3               1,3-propanediamine                                            4               1,4-butanediamine                                             5               1,5-pentanediamine                                            7               1,7-heptanediamine                                            8               1,8-octanediamine                                             ______________________________________                                    

    ______________________________________                                        m             dimethyl alkyldiimidate                                         ______________________________________                                        1             dimethyl malonimidate                                           2             dimethyl succinimidate                                          3             dimethyl glutarimidate                                          5             dimethyl pimelimidate                                           6             dimethyl octanediimidate                                        7             dimethyl nonanediimidate                                        8             dimethyl decanediimidate                                        9             dimethyl undecanediimidate                                      10            dimethyl dodecanediimidate                                      ______________________________________                                    

B. Assay Reagents

1. Antiserum--Rabbit anti-human IgG obtained from Calbiochem, La Jolla,Calif.

2. Enzyme and Buffer--Same as those described in Parts B-2 and B-3 inExample 9.

3. IgG standards--Pooled sera diluted 100-fold with the buffer.

4. Fluorogenic IgG Reagent--From Part A.

C. Assay Procedure and Results

To a plastic disposable cuvette was added sequentially 3.1 ml of thebuffer containing 0.28 nmole (89 nM) of the Fluorogenic IgG Reagent, 0.1ml of a selected standard, and 0.1 ml of the antiserum diluted 10-foldwith the buffer (sufficient to decrease the enzyme reaction to about 10%of that observed in the absence of antiserum). The cuvette was gentlyinverted for mixing and 0.1 ml of the enzyme solution containing 0.005units of β-galactosidase was added and mixed by inversion. The solutionwas incubated at room temperature for 30 minutes and the fluorescenceintensity measured with an Aminco-Bowman spectrofluorometer. Excitationand emission wavelengths were set at 400 and 450 nm, respectively, andall measurements were conducted at 25° C.

A standard curve generated for the assay of IgG according to thisprocedure is depicted in FIG. 15 of the drawings. The experiments wererepeated for assaying IgM and IgA. Labeled conjugates were preparedaccording to the synthetic method of Part A. Results were similar tothose for IgG.

What is claimed is:
 1. A β-galactosyl-umbelliferone-labeled conjugate ofthe formula: ##STR27## wherein R is a linking group and L is a proteinor polypeptide.
 2. The conjugate of claim 1 wherein L is an antibody. 3.The conjugate of claim 1 wherein said linking group is a chaincontaining between 1 to 10 carbon atoms and 0 to 5 heteroatoms selectedfrom nitrogen, oxygen and sulfur.
 4. The conjugate of claim 1 whereinsaid linking group is an amide bond.